



## Strathprints Institutional Repository

**Light, Jacob G. and Fransen, James W. and Adekunle, Adewumi N. and Adkins, Alice and Pangen, Gobinda and Loudin, James and Mathieson, Keith and Palanker, Daniel V. and McCall, Maureen A. and Pardue, Mabelle T. (2014) Inner retinal preservation in rat models of retinal degeneration implanted with subretinal photovoltaic arrays. *Experimental Eye Research*, 128. pp. 34-42. ISSN 0014-4835 , <http://dx.doi.org/10.1016/j.exer.2014.09.004>**

This version is available at <http://strathprints.strath.ac.uk/51489/>

**Strathprints** is designed to allow users to access the research output of the University of Strathclyde. Unless otherwise explicitly stated on the manuscript, Copyright © and Moral Rights for the papers on this site are retained by the individual authors and/or other copyright owners. Please check the manuscript for details of any other licences that may have been applied. You may not engage in further distribution of the material for any profitmaking activities or any commercial gain. You may freely distribute both the url (<http://strathprints.strath.ac.uk/>) and the content of this paper for research or private study, educational, or not-for-profit purposes without prior permission or charge.

Any correspondence concerning this service should be sent to Strathprints administrator: [strathprints@strath.ac.uk](mailto:strathprints@strath.ac.uk)

1 **Inner retinal preservation in rat models of retinal degeneration implanted with subretinal**  
2 **photovoltaic arrays**

3

4 **Jacob G. Light<sup>a,b</sup>, James W. Fransen<sup>c</sup>, Adewumi N. Adekunle<sup>a</sup>, Alice Adkins<sup>b</sup>, Gobinda**  
5 **Pangeni<sup>d</sup>, James Loudin<sup>e</sup>, Keith Mathieson<sup>e,g</sup>, Daniel V. Palanker<sup>e,f</sup>, Maureen A. McCall<sup>c,d</sup>,**  
6 **Machelle T. Pardue<sup>a,b</sup>.**

7 <sup>a</sup>Ophthalmology, Emory University; <sup>b</sup>Rehab R&D Center of Excellence, Atlanta VA Medical  
8 Center; <sup>c</sup>Anatomical Sciences & Neurobiology, <sup>d</sup>Ophthalmology & Visual Sciences, University of  
9 Louisville; <sup>e</sup>Hansen Experimental Physics Laboratory, <sup>f</sup>Ophthalmology, Stanford University;  
10 <sup>g</sup>Institute of Photonics, University of Strathclyde, UK

11

12 **Corresponding Author:**

13 Machelle T. Pardue, PhD  
14 Research Service (151Oph)  
15 Atlanta VA Medical Center  
16 1670 Clairmont Rd  
17 Decatur, GA 30033

18

19 Ph: 404-321-6111 x7342

20 Fax: 404-728-4847

21 [mpardue@emory.edu](mailto:mpardue@emory.edu)

22

23

24 **Abstract:**

25 Photovoltaic arrays (PVA) implanted into the subretinal space of patients with retinitis  
26 pigmentosa (RP) are designed to electrically stimulate the remaining inner retinal circuitry in  
27 response to incident light, thereby recreating a visual signal when photoreceptor function  
28 declines or is lost. Preservation of inner retinal circuitry is critical to the fidelity of this transmitted  
29 signal to ganglion cells and beyond to higher visual targets. Post-implantation loss of retinal  
30 interneurons or excessive glial scarring could diminish and/or eliminate PVA-evoked signal  
31 transmission. As such, assessing the morphology of the inner retina in RP animal models with  
32 subretinal PVAs is an important step in defining biocompatibility and predicting success of signal  
33 transmission. In this study, we used immunohistochemical methods to qualitatively and  
34 quantitatively compare inner retinal morphology after the implantation of a PVA in two RP  
35 models: the Royal College of Surgeons (RCS) or transgenic S334ter-line 3 (S334ter-3)  
36 rhodopsin mutant rat. Two PVA designs were compared. In the RCS rat, we implanted devices  
37 in the subretinal space at 4 weeks of age and histologically examined them at 8 weeks of age  
38 and found inner retinal morphology preservation with both PVA devices. In the S334ter-3 rat, we  
39 implanted devices at 6 to 12 weeks of age and again, inner retinal morphology was generally  
40 preserved with either PVA design 16 to 26 weeks post implantation. Specifically, the length of  
41 rod bipolar cells and numbers of cholinergic amacrine cells were maintained along with their  
42 characteristic inner plexiform lamination patterns. Throughout the implanted retinas we found  
43 nonspecific glial reaction, but none showed additional glial scarring at the implant site. Our  
44 results indicate that subretinally implanted PVAs are well-tolerated in rodent RP models and that  
45 the inner retinal circuitry is preserved, consistent with our published results showing implant-  
46 evoked signal transmission.

47 **Keywords:** retina, prosthetic, bipolar cells, amacrine cells, Müller glial cells

## 48 **1. Introduction**

49 Retinitis pigmentosa (RP) and age-related macular degeneration (AMD) are leading  
50 causes of irreversible blindness worldwide (Hartong et al., 2006). In these diseases, vision loss,  
51 regardless of underlying etiology, results from degeneration of retinal photoreceptors.  
52 Remodeling of the inner retina occurs in late stages of disease (Jones and Marc, 2005; Marc  
53 and Jones, 2003; Marc et al., 2007; Strettoi et al., 2002), but photoreceptor degeneration leaves  
54 the neurons and circuitry of the inner retina relatively intact for extended periods of time  
55 (Humayun et al., 1999; Jones et al., 2003; Marc and Jones, 2003; Marc et al., 2007; Strettoi et  
56 al., 2002; Strettoi et al., 2003).

57 One promising approach that targets the remaining retinal circuitry to restore lost vision  
58 uses prosthetic devices to functionally replace photoreceptors. Several different designs and  
59 placement strategies are currently being evaluated. Epiretinal placement and stimulation of the  
60 retinal ganglion cells (RGC) should require algorithms to selectively achieve information  
61 transmission (Jensen et al., 2005; Humayun et al., 2012). Suprachoroidal implants (Cicione et  
62 al., 2012; Kanda et al., 2004; Morimoto et al., 2011; Wong et al., 2009; Yamauchi et al., 2005)  
63 and subretinal microphotodiode arrays (Chow et al., 2001; Mathieson et al., 2012; Rizzo, 2011;  
64 Zrenner et al., 1999) are designed to directly stimulate bipolar cells and theoretically utilize  
65 network-mediated retinal stimulation, preserving the integrative properties of second order  
66 neurons in the inner plexiform layer (IPL) (Asher et al., 2007; Wang et al., 2012). Other  
67 strategies utilize optogenetics to confer light sensitivity to bipolar or RGCs (Bi et al., 2006;  
68 Busskamp et al., 2012; Garg and Federman, 2013; Isago et al., 2012; Lin et al., 2008; Tomita et  
69 al., 2007) to directly stimulate retinal tissues.

70 Subretinally placed photovoltaic arrays (PVAs) provide targeted stimulation to the inner  
71 nuclear layer (INL) (Fransen et al., 2014) due to their current density distribution and size

72 (Mathieson et al. 2012). Because bipolar cells are interneurons that connect photoreceptors to  
73 RGCs they are involved in signal transmission with PVAs. Retention of these cells and  
74 formation of a functional retinal-prosthetic interface would aid in visual restoration. For this to  
75 occur there must be a high level of biocompatibility between the retina and prosthesis. As such,  
76 measures of the integrity of the bipolar cells and other retinal constituents are critical  
77 components to the evaluation of the success of any subretinal prosthetic.

78 Previous studies have attempted to characterize the condition of implanted and/or  
79 electrically stimulated retinal tissue histologically and immunohistochemically (Alamusi et al.,  
80 2013; Chow et al., 2001; Pardue et al., 2001; Ray et al., 2009; Ray et al., 2011; Tamaki et al.,  
81 2008). However, many of these studies have examined the effects only of certain aspects of the  
82 treatment paradigm, such as acute electrical stimulation or biocompatibility of a prosthetic  
83 device in wild-type animals that do not exhibit degenerative pathology. In this study, we  
84 examined retinal morphology after implantation of two generations of subretinal silicon devices  
85 in two RP rat models. We compared a monopolar PVA (mPVA) with no perforations (Chow et  
86 al., 2001) to a bipolar PVA (bPVA), which includes bipolar pixels separated by 5  $\mu\text{m}$  gaps  
87 (Mathieson et al., 2012). Photovoltaic pixels in monopolar devices have individual active  
88 electrodes, but share a common large return electrode on the back side of the implant. Bipolar  
89 pixels are composed of 3 photodiodes in series, connected between the active electrode in the  
90 center of the pixel and a return electrode surrounding each pixel (Mathieson et al., 2012). All  
91 devices in the present study were photoactive. The bPVA gaps enhance proximity of the  
92 electrodes to inner retinal neurons and allow diffusion of extracellular milieu through the implant  
93 (Adkins et al., 2013; Mathieson et al., 2012). Since the subretinal PVA stimulates retinal  
94 neurons that are within close proximity to the electrode (Fransen et al., 2014), we focused our  
95 analysis on inner retinal cells that are likely activated by the PVA device. Rod bipolar cells and  
96 cholinergic amacrine cells represent well defined populations of cells with robust cellular

97 markers to assess overall inner retinal health. We also assessed glial reaction in tissues within  
98 and distal to the implant site from 16 to 26 weeks post implantation in the S334ter-3 and 4  
99 weeks post implantation in the RCS rat. Our results suggest that both the mPVA and bPVA  
100 designs are well tolerated and preserve the necessary inner retinal circuitry that underlie the  
101 transmission of signals to the RGCs and beyond (Fransen et al., 2014).

## 102 **2. Methods**

### 103 **2.1 Animals and Experimental Groups**

104 All animal procedures were approved by the Institutional Animal Care and Use  
105 Committee and conformed to the ARVO Statement for the Use of Animals in Ophthalmology  
106 and Vision Research. Two models of RP were used: the Royal College of Surgeons (RCS) and  
107 S334ter-3 rats from an in-house breeding colony originated from breeders donated by Dr.  
108 Matthew LaVail (University of California, San Francisco) (LaVail et al., 1975; Mullen and LaVail,  
109 1976).

110 The RCS rats (n=4) were implanted binocularly at 4 weeks of age and terminated 4  
111 weeks post-implantation. RCS rats exhibit a moderate rate of photoreceptor degeneration;  
112 approximately 50% of the initial ONL thickness was present at the age of implantation (LaVail  
113 and Battelle, 1975). Four eyes were implanted with an mPVA device and 4 with a bPVA device.  
114 The eyes were divided such that all bPVA-implanted eyes were processed as frozen sections  
115 for retinal cross-sections and half the mPVA eyes processed similarly with the remaining  
116 prepared as retinal flat mounts.

117 S334ter-3 rats were implanted monocularly (right eye) with either an mPVA (n=4) or a  
118 bPVA (n=7) from 6 to 12 weeks of age and were terminated at 22 to 32 weeks of age (16-26  
119 weeks of implantation). Monocular implantation accommodated superior colliculus recordings  
120 that are reported elsewhere (Fransen et al., 2014). The S334ter-3 is a rapid degeneration model

121 and most photoreceptors had degenerated at the time of implantation (McGill et al., 2012). All  
122 S334ter-3 eyes were processed as frozen sections. Additional cross sections were analyzed  
123 from three age-matched unimplanted control eyes from each RP strain, as well as 3 eyes from  
124 8-week-old Long Evans wild-type rats acquired from Charles River.

## 125 **2.2 Overview of Devices**

126 Two types of PVA were explored: mPVA and bPVA (Mathieson et al., 2012; Pardue et  
127 al., 2005b). mPVA devices, provided by Optobionics, Inc (Glen Ellyn, IL), were fabricated using  
128 previously described thin-film fabrication methods (Chow et al., 2001). The mPVA is a 1 mm  
129 diameter silicon disk, 25  $\mu\text{m}$  thick, containing 1200 microphotodiodes with active electrodes on  
130 one face and a common return electrode on the back, both coated with iridium oxide (Chow et  
131 al., 2001). The bPVA device's photovoltaic arrays were composed of triple-diode pixels  
132 fabricated on a silicon wafer. Each pixel contains an active electrode in its center and a return  
133 electrode at the circumference. Upon illumination with a pulse of light, each pixel generates a bi-  
134 phasic pulse of electric current flowing through the tissue between electrodes, primarily  
135 stimulating the inner nuclear layer (INL) cells (Fransen et al., 2014). Electrodes were coated in  
136 iridium oxide and the details of manufacturing methods of the bPVA were published previously  
137 (Wang et al., 2012). Five- $\mu\text{m}$  wide gaps were etched between adjacent pixels for electrical  
138 isolation and to improve nutrients flow through the implant (Mathieson, et al. 2012). The bPVA  
139 device measured 0.8 x 1.2 mm and was 30- $\mu\text{m}$  thick. bPVA devices were left in retinal tissue for  
140 histological analysis due to tissue destruction caused by removal.

141

## 142 **2.3 Surgical Procedure**

143 The surgical methods employed for implantation of the PVAs into the subretinal space  
144 have been described previously (Pardue et al., 2005b). Briefly, rats were anesthetized

145 [ketamine (60 mg/kg) and xylazine (7.5 mg/kg)] and placed into a sterile field. A traction suture  
146 was made at the superior limbus and the eye was rotated inferiorly. A ~1.0 mm incision was  
147 made in the superior globe reaching the vitreous. The eye was hydrated with a drop of saline,  
148 and a 10 minute waiting period was observed which allowed the retina to detach from the RPE.  
149 The PVA was then slid into the subretinal space with the electrodes in contact with the retina.  
150 Successful subretinal placement was confirmed via fundus examination and subsequent  
151 spectral domain-ocular coherence tomography (SD-OCT) imaging (Heidelberg HRA+OCT,  
152 Carlsbad, CA) (Fransen et al., 2014). Implants rested in the superior-temporal retina from 0.5 to  
153 1 mm from the optic nerve head.

## 154 **2.4 Immunohistochemistry**

### 155 **2.4.1 Cross-sections**

156 Following anesthesia [ketamine (60 mg/kg)/xylazine (7.5 mg/kg)] and sacrifice [390  
157 mg/mL pentobarbital sodium (Euthasol, Virbac AH, Inc., Fort Worth, TX)], eyes were  
158 immediately enucleated and fixed in 4% paraformaldehyde for 30 minutes. The posterior eyecup  
159 was bisected in the superior/inferior plane near the optic nerve, ensuring that the entire implant  
160 was intact and present in only one of the two resulting halves (Figure 1A). mPVA devices were  
161 gently extracted from the subretinal space using hydrodissection. bPVAs, which contain gaps  
162 through which the retinal tissue migrates (Palanker et al., 2004), were left in place to preserve  
163 retinal morphology around the implant. The tissue was cryoprotected overnight in 30% sucrose  
164 in 0.1M PBS and frozen in embedding medium (O.C.T. Tissue-Tek®, Sakura Finetek, Tokyo).  
165 Retinal sections in the superior/inferior plane (20-30  $\mu$ m) were cut on a cryostat and thaw-  
166 mounted on glass slides. Sections containing the implant site were mounted on the same slide  
167 with sections from the corresponding non-implanted half (referred to as “distal” tissue) so that  
168 both sections received equal reagent exposure.



169 Table 1 lists the antibodies used, along with working dilutions and sources. Rod bipolar  
170 cells were labeled with anti-protein kinase C alpha subunit (PKC $\alpha$ ) (Kosaka et al., 1998). Müller  
171 glial reaction in response to ocular stress was assessed with antibodies to glial fibrillary acidic  
172 protein (GFAP) (Bringmann et al., 2006). Finally, cholinergic amacrine cells and IPL lamination  
173 patterns were visualized with anti-choline acetyltransferase (ChAT) antibodies (Dijk and  
174 Kamphuis, 2004). The incubation protocol has been described previously (Lee et al., 2008).  
175 Briefly, following a wash in 1.0 M PBS slides were blocked for 1 hour at room temperature (10%  
176 donkey serum, 1% BSA, and 1% Triton X-100 in 1.0 M PBS). Primary and secondary antibodies  
177 were diluted in 1.0 M PBS containing 0.5% Triton X-100. Sections were incubated with primary  
178 antibodies overnight at 4°C and secondary antibodies for 2 hours at room temperature.  
179 Fluorescent secondary antibodies included donkey-anti-rabbit-DyLight® 488 (Abcam,  
180 Cambridge, MA) and donkey-anti-goat-DyLight® 594 (Abcam, Cambridge, MA), both diluted  
181 1:300. Sections were stained with DAPI, mounted with mounting medium (VectaShield® Hard  
182 Set, Vector Laboratories, Inc., Burlingame, CA), and coverslipped.

183 Sections were visualized and images taken on a confocal microscope (Eclipse Ti  
184 microscope with D-Eclipse C1 confocal controller, Nikon, Tokyo). Z-stack images spanning the  
185 section thickness at 1  $\mu$ m intervals were captured using a 40 X oil immersion lens directly under  
186 the implant site (“implanted”), immediately adjacent to the implant site (“adjacent”), and “distal”  
187 tissue from the non-implanted portion of the eye (see Figure 1A). Images of unimplanted control  
188 tissue were acquired from central, superior retinal sections. The Z-stack images were  
189 condensed into max-intensity volume projections and processed using commercial software  
190 (ImageJ, NIH, Bethesda, MD and Photoshop™6.0, Adobe Systems, Inc., San Jose, CA). For  
191 comparisons of cross sections, extended-focus confocal images were composed of a stack of  
192 26 images along the z-axis. ChAT flat mounted extended-focus confocal images were  
193 comprised of a stack of 5 planes, each 1  $\mu$ m thick. Pinhole size, gain, photo multiplier, and

194 offset of the confocal microscope were standardized within experimental groups. Brightness and  
195 contrast optimization was applied equally across all images, except images of GFAP-labeled  
196 sections in which no optimization was performed.

#### 197 **2.4.2 Quantification**

198 Digital confocal cross-sections were analyzed using an image program (Image J,  
199 National Institute of Health, Bethesda, MA). Cross-sections of immuno-labeled S334ter-3  
200 retinas, implanted with either mPVA or bPVA were quantified in the following ways: 1) the length  
201 of PKC $\alpha$  labeled rod bipolar cells were measured from the center of the soma to the axon  
202 terminals, 2) intensity of GFAP immunofluorescence was measured, and 3) the number of INL-  
203 placed and displaced (in RGC layer) ChAT-positive amacrine nuclei were counted. For each  
204 quantification, at least 2 sections from 2-4 retinas were analyzed. Triplicate measurements of  
205 rod bipolar cells from summed z-stack PKC $\alpha$ -labeled images were made on each section and  
206 averaged. GFAP immunoreactivity was quantified by measuring the intensity of a 55 x 40  $\mu$ m  
207 region of interest (ROI) beginning at the retinal ganglion cell layer extending into the inner  
208 plexiform layer and normalized to a background region without tissue of similar size. PKC $\alpha$  and  
209 GFAP data was normalized to the distal regions to compare implant designs between different  
210 ages. ChAT-labeled z-stacks were summed and the number of ChAT positive nuclei was  
211 measured along a 150- $\mu$ m length on each section.

212 Statistical comparisons between mPVA and bPVA devices from each retinal region were  
213 made with two-way repeated measures ANOVA using Holm-Sidak post-hoc comparisons  
214 (Sigmastat v3.5 ,Systat Software, San Jose, CA).

#### 215 **2.4.3 Flat mounts**

216 A subset of RCS eyes was processed as flat mounts, as described previously (Bernstein  
217 and Guo, 2011), with the following modifications. Eyes were enucleated and fixed in 4%

218 paraformaldehyde for 2 hours. The posterior eye cups were digested in hyaluronidase (1mg/mL;  
219 Sigma-Aldrich, St. Louis, MO) diluted 1:500 in 1.0 M PBS for 30 minutes. The retinas were  
220 carefully dissected from the retinal pigment epithelium (RPE), washed twice in PBST (0.5%  
221 Triton X-100 in 1.0M PBS), and then frozen in PBST at -80°C for 15 minutes. After thawing  
222 slowly at room temperature, the retina was washed twice in PBST, blocked (10% donkey serum,  
223 0.25% Triton X-100 in 1.0M PBS) for 4 hours at room temperature, and incubated in anti-ChAT  
224 antibody (Table 1) overnight at 4°C. After 3 washes in PBST, donkey-anti-goat-DyLight® 594  
225 secondary antibody (1:300; Abcam, Cambridge, MA) was applied for 1 hour at room  
226 temperature. Following additional washes, retinas were stained with DAPI, cut into a cloverleaf  
227 shape, and flattened on glass slides with the RGC layer face up. The retinas were mounted with  
228 mounting medium (VectaShield® Hard Set, Vector Laboratories, Inc., Burlingame, CA) and  
229 coverslipped.

230 The flat mounts were imaged using the confocal system, as described above, to  
231 generate Z-stack images over the implant site and distal regions of the same retina. 3D  
232 recreations were assembled and rotated using the 3D Viewer Plugin (ImageJ, NIH, Bethesda,  
233 MD). Contrast and brightness were optimized equally across images (Photoshop™6.0, Adobe  
234 Systems, Inc., San Jose, CA).

### 235 **3. Results**

#### 236 **3.1 Rod bipolar cells maintained in both implant designs and RP models**

237 Rod bipolar cells were labeled for PKC $\alpha$  in both RCS and S334ter-3 rat eyes implanted  
238 with either PVA design. Figure 1A shows a fundus image of an mPVA in an RCS rat and the  
239 superimposed colored lines indicate the areas of the retina sampled in each of the subsequent  
240 figures. Blue indicates the area within the implant site, red the area adjacent to and green the  
241 area distal to the implant site.

242 Figure 1 shows representative images of PKC $\alpha$  positive rod bipolar cells in wild-type  
243 (WT) (Figure 1B) and RCS rat retinas. An unimplanted RCS retina is shown in Figure 1F. The  
244 unimplanted and the implanted RCS retinas exhibited atrophy of rod bipolar cell dendritic tufts  
245 relative to WT. In implanted retinas, this was the case both within and outside implant sites. In  
246 all RCS retinas, rod bipolar cells retained the other aspects of their characteristic morphology;  
247 their somas were located near the outer margin of the INL and axon terminals in the distal IPL.  
248 In addition, they persisted across the retina, including within the implant site regardless of  
249 device design (Figure 1C, G). There were no apparent disruptions of rod bipolar cell morphology  
250 between implant site, adjacent, and distal sites for both bPVA and mPVA implants (compare  
251 Figure 1 C,G to D,H to E,I).

252 Implantation of subretinal devices in S334ter-3 rats had no effect on rod bipolar cell  
253 morphology. Unimplanted S334ter-3 control retinas (Figure 2E) showed a complete loss of rod  
254 bipolar cell dendritic arbors, disorganization of their somas, and a considerably thinner INL  
255 compared to WT (Figure 2A); demonstrating a more advanced retinal degeneration compared to  
256 RCS rats (Figures 1F and 2E). Similarly, S334ter-3 morphology of rod bipolar cells was  
257 comparable regardless of PVA design (Figure 2B-D and 2F-H). S334ter-3 rod bipolar cells  
258 retained their characteristic morphology with somas near the outer margin of the INL and axon  
259 terminals in the distal IPL. In addition, there was no apparent disruption of rod bipolar cell  
260 morphology between implant site, adjacent, and distal sites in the S334ter-3 rat (Figures 2B-D  
261 and F-H), regardless of device design. Quantification of the length of PKC $\alpha$  labeled rod bipolar  
262 cells in S344ter-3 rats showed no significant differences between mPVA and bPVA implanted  
263 rats or retinal location (Figure 3A; Two-way repeated ANOVA,  $p>0.05$ ).

### 264 **3.2 Cholinergic amacrine cells intact with implantation of PVA devices**

265           RCS and S334ter-3 sections were labeled with ChAT to explore the organization of the  
266 cholinergic amacrine cells and the laminar bands that their processes form in the IPL (Figure 4).  
267 The pattern of ChAT expression indicated that cholinergic amacrine cells survive within the  
268 implant site and both their somas and processes maintain WT IPL lamination patterns, with cell  
269 bodies in both the ganglion cell layer (GCL) and the innermost layer of the INL, and stratified  
270 processes within sublaminae a and b (Figure 4). RCS and S334ter-3 tissue showed identical  
271 expression patterns in unimplanted control, implanted, adjacent, and distal retinal tissue with  
272 implantation of the bPVA (Figure 4B-I). mPVA-implanted retinas maintained this typical pattern  
273 (data not shown). Counts of ChAT labeled nuclei in S334ter-3 eyes in both the INL and ganglion  
274 cell layer had a trend towards being lower in mPVA than bPVA, but did not differ statistically  
275 (Figure 3C, 3D; Two-way repeated ANOVA,  $p=0.111$  and  $p = 0.112$ , respectively). ChAT  
276 expression pattern also was examined *en face* in retinal flat mounts in a subset of RCS rats  
277 (Figure 5). The general distribution of ChAT-labeled cells was consistent between control and  
278 both mPVA implanted retinas for ChAT-labeled cells in both the INL and ganglion cell, which  
279 tiled the retina in a mosaic fashion as expected (Figure 5A vs 5B and 5C vs 5D, respectively).

### 280 **3.3 Müller cell glial reaction within normal limits after implantation**

281           Glial reaction within RCS and S334ter-3 retina was evaluated using expression of GFAP  
282 (Figure 6). RCS age-matched unimplanted retinas (Figure 6A) displayed strong GFAP labeling  
283 in Müller glial processes that extended from the nerve fiber layer (NFL) to the partially  
284 degenerated ONL. In bPVA implanted RCS retinas at 4 weeks post implantation (Figure 6B-D),  
285 the glial reaction within the implant site was similar to the reaction in adjacent and distal regions;  
286 we observed little to no additional glial scarring around the implant (Figure 6B). In fact, in many  
287 cases, GFAP labeling appeared to be less pronounced at the implant site (Figure 6B) relative to  
288 distal areas (Figure 6D). Similar results were found with mPVA devices (data not shown).

289 S334ter-3 age-matched unimplanted retinas showed intense GFAP labeling at the outer  
290 edge of the INL that was not seen in RCS retina (Figure 6A, E, I). This is consistent with the  
291 faster degeneration in this model and the formation of a glial seal that occurs after total  
292 photoreceptor degeneration (Jones et al., 2003). While glial reaction was widespread,  
293 persistent, and uniform in all S334ter-3 tissue, there was no noticeable difference in expression  
294 of GFAP by Müller glia in bPVA implanted retinas adjacent or distal to the implants (Figure 6J-  
295 L). Although the spatial extent of GFAP reaction was similar in mPVA implanted retinas (Figure  
296 6F-H), we observed a significant increase in GFAP intensity in mPVA devices compared to  
297 bPVA (Figure 3B; Two-way repeated ANOVA, main effect of device,  $F(1, 15) = 14.38$ ,  $p=0.02$ ;  
298 Figure 3B). The differences were greatest over the implant regions with bPVA-implanted retinas  
299 having less GFAP immunoreactivity.

#### 300 **4. Discussion**

301 The use of subretinal prostheses for the restoration of vision in patients with RP or AMD  
302 depends upon an intact inner retina (O'Brien et al., 2012). Thus, it is critical that implantation of  
303 a subretinal device does not cause a loss of inner retinal cells or excessive gliosis/fibrosis, as  
304 both would interfere with the retinal-prosthesis interface. We have shown that a functional  
305 connection that requires synaptic transmission within the inner retina drives PVA evoked  
306 responses in the superior colliculus (Fransen et al., 2014). Here we show that the morphological  
307 basis for this connectivity is an intact inner retina in subretinally-implanted m- and bPVA  
308 devices. In addition, we show that morphology is maintained in two RP rat models, one with  
309 direct photoreceptor degeneration, the other with RPE dysfunction induced photoreceptor  
310 degeneration. This indicates that the effect we observe is general. We assessed rod bipolar  
311 cells because they represent the primary transmission pathway from the PVA to the RGCs and  
312 cholinergic amacrine cells because they are one of the most numerous amacrine cells and their  
313 processes form well known sublaminae in the the IPL. Together the two measures provide a

314 general assessment of inner retinal cell organization. While it is well-established that the  
315 degenerating retina undergoes remodeling when all photoreceptors are lost (Gargini et al.,  
316 2007; Marc et al., 2003; Strettoi et al., 2002), we show that in these models, rod bipolar cells  
317 and cholinergic amacrine cells within the implant site continue to exhibit typical and well-  
318 preserved morphology. Both their somata and processes within the IPL show normal  
319 localization and lamination. Previous studies show that normal retinas respond to both acute  
320 epiretinal electrical stimulation (Ray et al., 2009; Ray et al., 2011), or chronic subretinal  
321 implantation (Chow et al., 2001; Pardue et al., 2001; Tamaki et al., 2008; Yu et al., 2009) with  
322 an upregulation of GFAP expression and degenerative changes to the dendrites of rod bipolar  
323 cells. One study in which photosensitive dye-coupled film was subretinally implanted into RCS  
324 rat eyes showed preservation within the implant site of rod bipolar cell morphology via PKC $\alpha$   
325 labeling (Alamusi et al., 2013), consistent with the findings we report here.

326         The increase in GFAP labeling in all unimplanted RCS and S334ter-3 retinas compared  
327 to WT (images not shown) is consistent with previous reports on retinal remodeling during  
328 degeneration (Marc and Jones, 2003; Zhao et al., 2012). Importantly, GFAP labeling in and  
329 around the implant site was similar to distal areas, suggesting that the glial reaction was not  
330 augmented by the presence of the PVA. Previous immunohistochemical studies of subretinal  
331 implants in animals with normal retinas have shown an increase in GFAP expression within the  
332 implant site (Chow et al., 2001; Pardue et al., 2001; Tamaki et al., 2008; Yu et al., 2009). It is  
333 feasible that any upregulation in GFAP due to implantation is masked when extensive gliosis  
334 due to photoreceptor degeneration is already present. Quantification of GFAP  
335 immunofluorescence showed a significant decrease in S334ter-3 retinas implanted with bPVAs  
336 compared to mPVAs. This may indicate that the gap design of the bPVA is more biocompatible  
337 with the retina and reduces the stress response. As the PVA devices are active and present  
338 electrical current to the underlying inner retina in response to light, it is possible that GFAP

339 expression in the Müller glia is tempered by neuroprotective effects of subretinal electrical  
340 stimulation, which have been characterized previously (Ciavatta et al., 2013; Pardue et al.,  
341 2005a; Pardue et al., 2005b).

342         The persistence of inner retinal cells and their intact organization under the implanted  
343 device are consistent with our finding that PVA evoked responses are retained in the superior  
344 colliculus and require inner retinal synaptic transmission (Fransen et al., 2014). Structural  
345 integrity is critical to the success of function using this subretinal approach to visual restoration.  
346 The presence of normal IPL sublamination suggests that other circuits that modulate the  
347 excitatory signal are retained and may provide even better RGC and central signals. When  
348 translated to the clinic, implantation will be performed at mid to late stage of photoreceptor  
349 degeneration, similar to the implantation stages used here in the RCS and S334ter-3 rats,  
350 respectively. The morphology of the retina implanted with both PVAs was similar, which also is  
351 consistent with the functional results (Fransen et al., 2014) suggesting good compatibility at  
352 both stages of degeneration.

353         The development of the next-generation bPVA is intended to improve upon the design of  
354 the mPVA device, which has already been implanted in human patients (Chow et al., 2010;  
355 Chow et al., 2004). Bipolar design of the pixel electrodes provides much tighter confinement of  
356 electric field, and appears to improve spatial resolution, compared to monopolar arrangement in  
357 mPVAs (Fransen et al., 2014). Our comparisons between mPVA- and bPVA-implanted retinas  
358 and the reduced glial reaction in the retinas implanted with the bPVA device with the gaps  
359 between pixels suggests improved biocompatibility and may indicate a longer duration of the  
360 interface between the device and the retina, which needs to be tested empirically.

## 361 **5. Conclusions**



362 We found that both mPVA and bPVA devices implanted into the subretinal space were  
 363 well tolerated by the inner retina in two rat models of RP with regard to rod bipolar, cholinergic  
 364 amacrine, and Müller cell morphology. This initial analysis could be complemented with assays  
 365 of other cell types (such as cone bipolar cells, horizontal cells as well as other amacrine cell  
 366 classes). Other functional analyses could be aimed at examining the RGC responses and the  
 367 timing and spatial distribution of their excitatory and inhibitory inputs. With our findings this  
 368 would provide a complete understanding of the morphological and functional status of the inner  
 369 retina in contact with the prosthesis.

370 **Acknowledgements**

371 Funding was provided by the National Institutes of Health (R01-EY018608), the Air Force Office  
 372 of Scientific Research (FA9550-04), NIH CTSA (UL1 RR025744, Stanford Spectrum fund) and a  
 373 Stanford Bio-X IIP grant. K.M. was supported by an SU2P fellowship as part of an RCUK  
 374 Science Bridges award. J.F. was supported by an NIH T32 grant (5 T32 HL 76138-09). M.T.P.  
 375 was supported by a Research Career Scientist Award from the Department of Veterans Affairs.

376

377 **Table 1: Primary antibodies used in this study to characterize inner retinal health.**

Antigen	Antiserum	Source	Working Dilution	Cellular Target
PKC $\alpha$	Polyclonal rabbit anti-PKC $\alpha$	Santa Cruz Biotechnology, Inc., Dallas, TX	1:2000	Rod bipolar cells
GFAP	Polyclonal rabbit anti-GFAP	Abcam, Cambridge, MA	1:500	Glial reaction in retinal Müller cells
ChAT	Polyclonal goat anti-ChAT	Millipore, Billerica, MA	1:100	Cholinergic amacrine cells

378

379 **Figures Captions**

380 **Figure 1.** A) Sample fundus image of an RCS rat eye implanted subretinally with an mPVA.  
381 White dotted line indicates location of the cut made in the superior to inferior plane bisecting the  
382 posterior eye cup into implanted and non-implanted halves. “Implanted” region is indicated by  
383 the blue line. The area immediately “adjacent” to the implant site is shown by the red line. The  
384 green line displays an area opposite the implant within the non-implanted half, referred to as a  
385 “distal” area. The implant is 1mm in diameter. PKC $\alpha$  labeling in retinal cross-sections from WT  
386 rats (B), unimplanted control RCS rats at 2 months of age (F), RCS rats implanted from 4 to 8  
387 weeks postnatal with a bPVA (C-E) and or mPVA (G-I). Rod bipolar cells are present with well-  
388 preserved morphology and localization at the implant site (C and G) relative to adjacent (D and  
389 H) and distal (E and I) regions. Implanted eyes show PKC $\alpha$  labeling consistent with that of age-  
390 matched unimplanted RCS controls (F). Wild-type retinas (B) appear to exhibit more intact  
391 dendritic tufts, but somata and axon terminal localization is comparable to that in RCS tissue.  
392 Insets 1B, 1C, 1 F & 1G show magnified images of the dendritic tufts in the OPL. ONL=outer  
393 nuclear layer, OPL=outer plexiform layer, INL=inner nuclear layer, IPL=inner plexiform layer,  
394 GCL=ganglion cell layer. Scale bar=50 $\mu$ m.

395 **Figure 2.** PKC $\alpha$  labeling in retinal cross-sections from S334ter-3 rats implanted with a bPVA (B-  
396 D, implanted from 7 to 27 weeks postnatal) or mPVA (F-H, implanted from 6 to 27 weeks  
397 postnatal). Implanted sections (B and F) show rod bipolar cell morphology that is comparable to  
398 that in adjacent (C and G) and distal (D and H) areas. The morphology and localization of these  
399 sections is consistent with that seen in age-matched unimplanted S334ter-3 controls (E).  
400 However, all S334ter-3 tissues exhibit virtually complete loss of the ONL and rod bipolar cell  
401 dendrites, both of which are still evident in wild-type retina (A). Scale bar=50 $\mu$ m.

402 **Figure 3.** PKC $\alpha$ , GFAP, and ChAT labeling quantification. The relative length of PKC $\alpha$ -labeled  
403 bipolar cells (A) did not show significant differences between retinal region or implant types. The  
404 intensity of GFAP immunoreactivity (B) did not show significant differences between the retinal

405 location within each implant type, but did show a difference between implant types (Two-way  
406 repeated ANOVA,  $F(1, 15) = 14.38$   $p = 0.02$ ,  $n = 6$ ). Immunoreactivity was normalized to the  
407 distal position for the PKC $\alpha$  and GFAP labeling. ChAT immunoreactive cell counts did not show  
408 significant differences between retinal location or implant type for either INL placed (C) or  
409 displaced (D) cholinergic amacrine cells. Error bars represent standard error of the mean.

410 **Figure 4.** ChAT labeling in retinal cross-sections from RCS eyes (C-E, implanted from 4 to 8  
411 weeks postnatal) and S334ter-3 eyes (G-I, implanted from 7 to 27 weeks postnatal) with bPVA  
412 devices. Both RCS (B-E) and S334ter-3 sections (F-I), like wild-type (A), show typical  
413 cholinergic amacrine cell morphology with somata in the INL and GCL and processes in a dual-  
414 lamination pattern within the IPL. ChAT labeling patterns in implanted areas (C and G) are  
415 identical to those in adjacent (D and H), distal (E and I), Scale bar=50 $\mu$ m.

416 **Figure 5.** ChAT-labeled retinal flat mounts from RCS rats implanted from 4 to 8 weeks postnatal  
417 with an mPVA device (C and D) compared to unimplanted control eyes (A and B). *En face* view  
418 of unimplanted INL placed (A) and implanted INL placed (C) ChAT positive amacrine cells  
419 shows similar cholinergic amacrine cell distribution with consistent density. Similarly, labelling  
420 patterns of ChAT positive amacrine cells in the ganglion cell layer were consistent between  
421 unimplanted (B) and implanted (D) retinas. Scale bar=50 $\mu$ m.

422

423 **Figure 6.** GFAP labeling in retinal cross-sections from RCS (B-D) with bPVA and S334ter-3  
424 eyes with mPVA (F-H) and bPVA (K-L) devices. RCS were implanted 4 to 8 weeks postnatally,  
425 while the S334ter-3 animals were implanted at 12 to 32 weeks. Glial reaction is widespread in  
426 all RCS tissue (A-D), but implanted areas (B) do not show increased GFAP labeling in  
427 comparison with adjacent (C), distal (D), and age-matched unimplanted control (A) sections.  
428 Similar to RCS tissue, S334ter-3 sections (E-L) show widespread gliosis due to photoreceptor  
429 degeneration. However, GFAP labeling is not augmented in implanted regions (F and J) relative

430 to adjacent (G and K), distal (H and L), and age-matched unimplanted control section (E).  
431 S334ter-3 retinas display a characteristic glial seal above the INL, not seen in wild-type retinas  
432 (data not shown), consistent with advanced photoreceptor degeneration. NFL=nerve fiber layer.  
433 Scale bar=50 $\mu$ m.

434

435

436

437

438

439

440

441

442

443

444

445

446

447

448

449

450

451

452

453

454

455

456 **References**

- 457 Adkins, A., Wang, W., Kaplan, H., Emery, D., Fernandez de Castro, J., Lee, S.-J., Huie, P.,  
458 Palanker, D., McCall, M., Pardue, M., 2013. Morphological comparisons of flat and 3-  
459 dimensional subretinal photovoltaic arrays in rat and pig models of retinitis pigmentosa.  
460 Invest. Ophthalmol. Vis. Sci. 54, 1038.
- 461 Alamusi, Matsuo, T., Hosoya, O., Tsutsui, K.M., Uchida, T., 2013. Behavior tests and  
462 immunohistochemical retinal response analyses in RCS rats with subretinal implantation  
463 of Okayama-University-type retinal prosthesis. J. Artif. Organs 16, 343-351.
- 464 Asher, A., Segal, W.A., Baccus, S.A., Yaroslavsky, L.P., Palanker, D.V., 2007. Image  
465 processing for a high-resolution optoelectronic retinal prosthesis. IEEE Trans. Biomed.  
466 Eng. 54, 993-1004.
- 467 Bernstein, S.L., Guo, Y., 2011. Changes in cholinergic amacrine cells after rodent anterior  
468 ischemic optic neuropathy (rAION). Invest. Ophthalmol. Vis. Sci. 52, 904-910.
- 469 Bi, A.D., Cui, J.J., Ma, Y.P., Olshevskaya, E., Pu, M.L., Dizhoor, A.M., Pan, Z.H., 2006. Ectopic  
470 expression of a microbial-type rhodopsin restores visual responses in mice with  
471 photoreceptor degeneration. Neuron 50, 23-33.
- 472 Bringmann, A., Pannicke, T., Grosche, J., Francke, M., Wiedemann, P., Skatchkov, S.N.,  
473 Osborne, N.N., Reichenbach, A., 2006. Muller cells in the healthy and diseased retina.  
474 Prog. Retin. Eye Res. 25, 397-424.
- 475 Busskamp, V., Picaud, S., Sahel, J.A., Roska, B., 2012. Optogenetic therapy for retinitis  
476 pigmentosa. Gene Ther. 19, 169-175.
- 477 Chow, A.Y., Bittner, A.K., Pardue, M.T., 2010. The artificial silicon retina in retinitis pigmentosa  
478 patients (an American Ophthalmological Association thesis). Trans. of the Am.  
479 Ophthalmol. Soc. 108, 120-154.

480 Chow, A.Y., Chow, V.Y., Packo, K.H., Pollack, J.S., Peyman, G.A., Schuchard, R., 2004. The  
481 artificial silicon retina microchip for the treatment of vision loss from retinitis pigmentosa.  
482 Arch. Ophthalmol. 122, 460-469.

483 Chow, A.Y., Pardue, M.T., Chow, V.Y., Peyman, G.A., Liang, C., Perlman, J.I., Peachey, N.S.,  
484 2001. Implantation of silicon chip microphotodiode arrays into the cat subretinal space.  
485 IEEE Trans. Neural Syst. Rehabil. Eng. 9, 86-95.

486 Ciavatta, V.T., Mocko, J.A., Kim, M.K., Pardue, M.T., 2013. Subretinal electrical stimulation  
487 preserves inner retinal function in RCS rat retina. Mol. Vis. 19, 995-1005.

488 Cicione, R., Shivdasani, M.N., Fallon, J.B., Luu, C.D., Allen, P.J., Rathbone, G.D., Shepherd,  
489 R.K., Williams, C.E., 2012. Visual cortex responses to suprachoroidal electrical  
490 stimulation of the retina: effects of electrode return configuration. J. Neural Eng. 9,  
491 036009.

492 Dijk, F., Kamphuis, W., 2004. An immunocytochemical study on specific amacrine cell  
493 subpopulations in the rat retina after ischemia. Brain Res. 1026, 205-217.

494 Fransen, J. W., Pangen, G., Pardue, M.T., McCall, M.A. 2014. Local signaling from a retinal  
495 prosthetic in a rodent retinitis pigmentosa model in vivo. J. Neural Eng. 11, 046012.

496 Garg, S.J., Federman, J., 2013. Optogenetics, visual prosthesis and electrostimulation for  
497 retinal dystrophies. Curr. Opin. Ophthalmol. 24, 407-414.

498 Gargini, C., Terzibasi, E., Mazzoni, F., Strettoi, E., 2007. Retinal organization in the retinal  
499 degeneration 10 (rd10) mutant mouse: a morphological and ERG study. J. Comp.  
500 Neurol. 500, 222-238.

501 Grünert, U., Martin, P.R., 1991. Rod bipolar cells in the macaque monkey retina:  
502 immunoreactivity and connectivity. J Neurosci. 11, 2742-2758.

503 Hartong, D.T., Berson, E.L., Dryja, T.P., 2006. Retinitis pigmentosa. Lancet 368, 1795-1809.

504 Humayun, M.S., Dorn, J.D., da Cruz, L., Dagnelie, G., Sahel, J.A., Stanga, P.E., Cideciyan,  
505 A.V., Duncan, J.L., Elliott, D., Filley, E., Ho, A.C., Santos, A., Safran, A.B., Arditi, A., Del

506 Priore, L.V., Greenberg, R.J., Argus, I.I.S.G., 2012. Interim results from the international  
507 trial of Second Sight's visual prosthesis. *Ophthalmology* 119, 779-788.

508 Humayun, M.S., Prince, M., de Juan, E., Barron, Y., Moskowitz, M., Klock, I.B., Milam, A.H.,  
509 1999. Morphometric analysis of the extramacular retina from postmortem eyes with  
510 retinitis pigmentosa. *Invest. Ophthalmol. Vis. Sci.* 40, 143-148.

511 Isago, H., Sugano, E., Wang, Z., Murayama, N., Koyanagi, E., Tamai, M., Tomita, H., 2012.  
512 Age-Dependent Differences in Recovered Visual Responses in Royal College of  
513 Surgeons Rats Transduced with the Channelrhodopsin-2 Gene. *J. of Mol. Neurosci.* 46,  
514 393-400.

515 Jensen, R.J., Ziv, O.R., Rizzo, J.F., 2005. Responses of rabbit retinal ganglion cells to electrical  
516 stimulation with an epiretinal electrode. *J. Neural Eng.* 2, S16-21.

517 Jones, B.W., Watt, C.B., Frederick, J.M., Baehr, W., Chen, C.K., Levine, E.M., Milam, A.H.,  
518 Lavail, M.M., Marc, R.E., 2003. Retinal remodeling triggered by photoreceptor  
519 degenerations. *J. Comp. Neurol.* 464, 1-16.

520 Jones, B.W., Marc, R.E., 2005. Retinal remodeling during retinal degeneration. *Exp. Eye Res.*  
521 81, 123-137.

522 Kanda, H., Morimoto, T., Fujikado, T., Tano, Y., Fukuda, Y., Sawai, H., 2004.  
523 Electrophysiological studies of the feasibility of suprachoroidal-transretinal stimulation for  
524 artificial vision in normal and RCS rats. *Invest. Ophthalmol. Vis. Sci.* 45, 560-566.

525 Kosaka, J., Suzuki, A., Morii, E., Nomura, S., 1998. Differential localization and expression of  
526 alpha and beta isoenzymes of protein kinase C in the rat retina. *J. Neurosci. Res.* 54,  
527 655-663.

528 LaVail, M.M., Battelle, B.A., 1975. Influence of eye pigmentation and light deprivation on  
529 inherited retinal dystrophy in the rat. *Exp. Eye Res.* 21, 167-192.

530 LaVail, M.M., Sidman, R.L., Gerhardt, C.O., 1975. Congenic strains of RCS rats with inherited  
531 retinal dystrophy. *J. Hered.* 66, 242-244.

532 Lee, E.J., Padilla, M., Merwine, D.K., Grzywacz, N.M., 2008. Developmental regulation of the  
533 morphology of mouse retinal horizontal cells by visual experience. *Eur. J. Neurosci.* 27,  
534 1423-1431.

535 Lin, B., Koizumi, A., Tanaka, N., Panda, S., Masland, R.H., 2008. Restoration of visual function  
536 in retinal degeneration mice by ectopic expression of melanopsin. *Proc. Natl. Acad. Sci.*  
537 U.S.A. 105, 16009-16014.

538 Mandel, Y., Goetz, G., Lavinsky, D., Huie, P., Mathieson, K., Wang, L., Kamins, T., Galambos,  
539 L., Manivanh, R., Harris, J., Palanker, D., 2013. Cortical responses elicited by  
540 photovoltaic subretinal prostheses exhibit similarities to visually evoked potentials. *Nat.*  
541 *Commun.* 4, 1980.

542 Marc, R.E., Jones, B.W., 2003. Retinal remodeling in inherited photoreceptor degenerations.  
543 *Mol. Neurobiol.* 28, 139-147.

544 Marc, R.E., Jones, B.W., Anderson, J.R., Kinard, K., Marshak, D.W., Wilson, J.H., Wensel, T.,  
545 Lucas, R.J., 2007. Neural reprogramming in retinal degeneration. *Invest. Ophthalmol.*  
546 *Vis. Sci.* 48, 3364-3371.

547 Marc, R.E., Jones, B.W., Watt, C.B., Strettoi, E., 2003. Neural remodeling in retinal  
548 degeneration. *Prog. Retin. Eye Res.* 22, 607-655.

549 Mathieson, K., Loudin, J., Goetz, G., Huie, P., Wang, L., Kamins, T.I., Galambos, L., Smith, R.,  
550 Harris, J.S., Sher, A., Palanker, D., 2012. Photovoltaic Retinal Prosthesis with High Pixel  
551 Density. *Nat. Photonics* 6, 391-397.

552 McGill, T.J., Prusky, G.T., Douglas, R.M., Yasumura, D., Matthes, M.T., Lowe, R.J., Duncan,  
553 J.L., Yang, H., Ahern, K., Daniello, K.M., Silver, B., LaVail, M.M., 2012. Discordant  
554 anatomical, electrophysiological, and visual behavioral profiles of retinal degeneration in  
555 rat models of retinal degenerative disease. *Invest. Ophthalmol. Vis. Sci.* 53, 6232-6244.

556 Morimoto, T., Kamei, M., Nishida, K., Sakaguchi, H., Kanda, H., Ikuno, Y., Kishima, H., Maruo,  
557 T., Konoma, K., Ozawa, M., Nishida, K., Fujikado, T., 2011. Chronic Implantation of



558 Newly Developed Suprachoroidal-Transretinal Stimulation Prosthesis in Dogs. Invest.  
559 Ophthalmol. Vis. Sci. 52, 6785-6792.

560 Mullen, R.J., LaVail, M.M., 1976. Inherited retinal dystrophy: primary defect in pigment  
561 epithelium determined with experimental rat chimeras. Science 192, 799-801.

562 O'Brien, E.E., Greferath, U., Vessey, K.A., Jobling, A.I., Fletcher, E.L., 2012. Electronic  
563 restoration of vision in those with photoreceptor degenerations. Clin. Exp. Optom. 95,  
564 473-483.

565 Palanker, D., Huie, P., Vankov, A., Aramant, R., Seiler, M., Fishman, H., Marmor, M.,  
566 Blumenkranz, M., 2004. Migration of retinal cells through a perforated membrane:  
567 implications for a high-resolution prosthesis. Invest. Ophthalmol. Vis. Sci. 45, 3266-3270.

568 Pardue, M.T., Phillips, M.J., Yin, H., Fernandes, A., Cheng, Y., Chow, A.Y., Ball, S.L., 2005a.  
569 Possible sources of neuroprotection following subretinal silicon chip implantation in RCS  
570 rats. J. Neural Eng. 2, S39-47.

571 Pardue, M.T., Phillips, M.J., Yin, H., Sippy, B.D., Webb-Wood, S., Chow, A.Y., Ball, S.L., 2005b.  
572 Neuroprotective effect of subretinal implants in the RCS rat. Invest. Ophthalmol. Vis. Sci.  
573 46, 674-682.

574 Pardue, M.T., Stubbs, E.B., Jr., Perlman, J.I., Narfstrom, K., Chow, A.Y., Peachey, N.S., 2001.  
575 Immunohistochemical studies of the retina following long-term implantation with  
576 subretinal microphotodiode arrays. Exp. Eye Res. 73, 333-343.

577 Ray, A., Colodetti, L., Weiland, J.D., Hinton, D.R., Humayun, M.S., Lee, E.J., 2009.  
578 Immunocytochemical analysis of retinal neurons under electrical stimulation. Brain Res.  
579 1255, 89-97.

580 Ray, A., Lee, E.J., Humayun, M.S., Weiland, J.D., 2011. Continuous electrical stimulation  
581 decreases retinal excitability but does not alter retinal morphology. J. Neural Eng. 8,  
582 045003.

583 Rizzo, J.F., 3rd, 2011. Update on retinal prosthetic research: the Boston Retinal Implant Project.  
584 J. Neuroophthalmol. 31, 160-168.

585 Strettoi, E., Porciatti, V., Falsini, B., Pignatelli, V., Rossi, C., 2002. Morphological and functional  
586 abnormalities in the inner retina of the rd/rd mouse. J. Neurosci. 22, 5492-5504.

587 Strettoi, E., Pignatelli, V., Rossi, C., Porciatti, V., Falsini, B., 2003. Remodeling of second-order  
588 neurons in the retina of rd/rd mutant mice. Vision Research 43, 867–877.

589 Tamaki, T., Matsuo, T., Hosoya, O., Tsutsui, K.M., Uchida, T., Okamoto, K., Uji, A., Ohtsuki, H.,  
590 2008. Glial reaction to photoelectric dye-based retinal prostheses implanted in the  
591 subretinal space of rats. J. Artif. Organs 11, 38-44.

592 Tomita, H., Sugano, E., Yawo, H., Ishizuka, T., Isago, H., Narikawa, S., Kugler, S., Tamai, M.,  
593 2007. Restoration of visual response in aged dystrophic RCS rats using AAV-mediated  
594 channelopsin-2 gene transfer. Invest. Ophthalmol. Vis. Sci. 48, 3821-3826.

595 Uji, A., Matsuo, T., Ishimaru, S., Kajiura, A., Shimamura, K., Ohtsuki, H., Dan-oh, Y., Suga, S.,  
596 2005. Photoelectric dye-coupled polyethylene film as a prototype of retinal prostheses.  
597 Artif. Organs 29, 53-57.

598 Wang, L., Mathieson, K., Kamins, T.I., Loudin, J.D., Galambos, L., Goetz, G., Sher, A., Mandel,  
599 Y., Huie, P., Lavinsky, D., Harris, J.S., Palanker, D.V., 2012. Photovoltaic retinal  
600 prosthesis: implant fabrication and performance. J. Neural Eng. 9, 046014.

601 Wong, Y.T., Chen, S.C., Seo, J.M., Morley, J.W., Lovell, N.H., Suaning, G.J., 2009. Focal  
602 activation of the feline retina via a suprachoroidal electrode array. Vis. Res. 49, 825-833.

603 Yamauchi, Y., Franco, L.M., Jackson, D.J., Naber, J.F., Ziv, R.O., Rizzo, J.F., Kaplan, H.J.,  
604 Enzmann, V., 2005. Comparison of electrically evoked cortical potential thresholds  
605 generated with subretinal or suprachoroidal placement of a microelectrode array in the  
606 rabbit. J. Neural Eng. 2, S48-56.

607 Yu, W., Wang, X., Zhao, C., Yang, Z., Dai, R., Dong, F., 2009. Biocompatibility of subretinal  
608 parylene-based Ti/Pt microelectrode array in rabbit for further artificial vision studies. *J.*  
609 *Ocul. Biol. Dis. Infor.* 2, 33-36.

610 Zhao, T., Li, Y., Weng, C., Yin, Z., 2012. The changes of potassium currents in RCS rat Muller  
611 cell during retinal degeneration. *Brain Res.* 1427, 78-87.

612 Zrenner, E., Stett, A., Weiss, S., Aramant, R.B., Guenther, E., Kohler, K., Miliczek, K.D., Seiler,  
613 M.J., Haemmerle, H., 1999. Can subretinal microphotodiodes successfully replace  
614 degenerated photoreceptors? *Vis. Res.* 39, 2555-2567.

615

616

1 **Inner retinal preservation in rat models of retinal degeneration implanted with subretinal**  
2 **photovoltaic arrays**

3

4 **Jacob G. Light<sup>a,b</sup>, James W. Fransen<sup>c</sup>, Adewumi N. Adekunle<sup>a</sup>, Alice Adkins<sup>b</sup>, Gobinda**  
5 **Pangeni<sup>d</sup>, James Loudin<sup>e</sup>, Keith Mathieson<sup>e,g</sup>, Daniel V. Palanker<sup>e,f</sup>, Maureen A. McCall<sup>c,d</sup>,**  
6 **Machelle T. Pardue<sup>a,b</sup>.**

7 <sup>a</sup>Ophthalmology, Emory University; <sup>b</sup>Rehab R&D Center of Excellence, Atlanta VA Medical  
8 Center; <sup>c</sup>Anatomical Sciences & Neurobiology, <sup>d</sup>Ophthalmology & Visual Sciences, University of  
9 Louisville; <sup>e</sup>Hansen Experimental Physics Laboratory, <sup>f</sup>Ophthalmology, Stanford University;  
10 <sup>g</sup>Institute of Photonics, University of Strathclyde, UK

11

12 **Corresponding Author:**

13 Machelle T. Pardue, PhD  
14 Research Service (151Oph)  
15 Atlanta VA Medical Center  
16 1670 Clairmont Rd  
17 Decatur, GA 30033

18

19 Ph: 404-321-6111 x7342

20 Fax: 404-728-4847

21 [mpardue@emory.edu](mailto:mpardue@emory.edu)

22

23

24 **Abstract:**

25 Photovoltaic arrays (PVA) implanted into the subretinal space of patients with retinitis  
26 pigmentosa (RP) are designed to electrically stimulate the remaining inner retinal circuitry in  
27 response to incident light, thereby recreating a visual signal when photoreceptor function  
28 declines or is lost. Preservation of inner retinal circuitry is critical to the fidelity of this transmitted  
29 signal to ganglion cells and beyond to higher visual targets. Post-implantation loss of retinal  
30 interneurons or excessive glial scarring could diminish and/or eliminate PVA-evoked signal  
31 transmission. As such, assessing the morphology of the inner retina in RP animal models with  
32 subretinal PVAs is an important step in defining biocompatibility and predicting success of signal  
33 transmission. In this study, we used immunohistochemical methods to qualitatively and  
34 quantitatively compare inner retinal morphology after the implantation of a PVA in two RP  
35 models: the Royal College of Surgeons (RCS) or transgenic S334ter-line 3 (S334ter-3)  
36 rhodopsin mutant rat. Two PVA designs were compared. In the RCS rat, we implanted devices  
37 in the subretinal space at 4 weeks of age and histologically examined them at 8 weeks of age  
38 and found inner retinal morphology preservation with both PVA devices. In the S334ter-3 rat, we  
39 implanted devices at 6 to 12 weeks of age and again, inner retinal morphology was generally  
40 preserved with either PVA design 16 to 26 weeks post implantation. Specifically, the length of  
41 rod bipolar cells and numbers of cholinergic amacrine cells were maintained along with their  
42 characteristic inner plexiform lamination patterns. Throughout the implanted retinas we found  
43 nonspecific glial reaction, but none showed additional glial scarring at the implant site. Our  
44 results indicate that subretinally implanted PVAs are well-tolerated in rodent RP models and that  
45 the inner retinal circuitry is preserved, consistent with our published results showing implant-  
46 evoked signal transmission.

47 **Keywords:** retina, prosthetic, bipolar cells, amacrine cells, Müller glial cells

## 48 **1. Introduction**

49 Retinitis pigmentosa (RP) and age-related macular degeneration (AMD) are leading  
50 causes of irreversible blindness worldwide (Hartong et al., 2006). In these diseases, vision loss,  
51 regardless of underlying etiology, results from degeneration of retinal photoreceptors.  
52 Remodeling of the inner retina occurs in late stages of disease (Jones and Marc, 2005; Marc  
53 and Jones, 2003; Marc et al., 2007; Strettoi et al., 2002), but photoreceptor degeneration leaves  
54 the neurons and circuitry of the inner retina relatively intact for extended periods of time  
55 (Humayun et al., 1999; Jones et al., 2003; Marc and Jones, 2003; Marc et al., 2007; Strettoi et  
56 al., 2002; Strettoi et al., 2003).

57 One promising approach that targets the remaining retinal circuitry to restore lost vision  
58 uses prosthetic devices to functionally replace photoreceptors. Several different designs and  
59 placement strategies are currently being evaluated. Epiretinal placement and stimulation of the  
60 retinal ganglion cells (RGC) should require algorithms to selectively achieve information  
61 transmission (Jensen et al., 2005; Humayun et al., 2012). Suprachoroidal implants (Cicione et  
62 al., 2012; Kanda et al., 2004; Morimoto et al., 2011; Wong et al., 2009; Yamauchi et al., 2005)  
63 and subretinal microphotodiode arrays (Chow et al., 2001; Mathieson et al., 2012; Rizzo, 2011;  
64 Zrenner et al., 1999) are designed to directly stimulate bipolar cells and theoretically utilize  
65 network-mediated retinal stimulation, preserving the integrative properties of second order  
66 neurons in the inner plexiform layer (IPL) (Asher et al., 2007; Wang et al., 2012). Other  
67 strategies utilize optogenetics to confer light sensitivity to bipolar or RGCs (Bi et al., 2006;  
68 Busskamp et al., 2012; Garg and Federman, 2013; Isago et al., 2012; Lin et al., 2008; Tomita et  
69 al., 2007) to directly stimulate retinal tissues.

70 Subretinally placed photovoltaic arrays (PVAs) provide targeted stimulation to the inner  
71 nuclear layer (INL) (Fransen et al., 2014) due to their current density distribution and size

72 (Mathieson et al. 2012). Because bipolar cells are interneurons that connect photoreceptors to  
73 RGCs they are involved in signal transmission with PVAs. Retention of these cells and  
74 formation of a functional retinal-prosthetic interface would aid in visual restoration. For this to  
75 occur there must be a high level of biocompatibility between the retina and prosthesis. As such,  
76 measures of the integrity of the bipolar cells and other retinal constituents are critical  
77 components to the evaluation of the success of any subretinal prosthetic.

78 Previous studies have attempted to characterize the condition of implanted and/or  
79 electrically stimulated retinal tissue histologically and immunohistochemically (Alamusi et al.,  
80 2013; Chow et al., 2001; Pardue et al., 2001; Ray et al., 2009; Ray et al., 2011; Tamaki et al.,  
81 2008). However, many of these studies have examined the effects only of certain aspects of the  
82 treatment paradigm, such as acute electrical stimulation or biocompatibility of a prosthetic  
83 device in wild-type animals that do not exhibit degenerative pathology. In this study, we  
84 examined retinal morphology after implantation of two generations of subretinal silicon devices  
85 in two RP rat models. We compared a monopolar PVA (mPVA) with no perforations (Chow et  
86 al., 2001) to a bipolar PVA (bPVA), which includes bipolar pixels separated by 5  $\mu\text{m}$  gaps  
87 (Mathieson et al., 2012). Photovoltaic pixels in monopolar devices have individual active  
88 electrodes, but share a common large return electrode on the back side of the implant. Bipolar  
89 pixels are composed of 3 photodiodes in series, connected between the active electrode in the  
90 center of the pixel and a return electrode surrounding each pixel (Mathieson et al., 2012). All  
91 devices in the present study were photoactive. The bPVA gaps enhance proximity of the  
92 electrodes to inner retinal neurons and allow diffusion of extracellular milieu through the implant  
93 (Adkins et al., 2013; Mathieson et al., 2012). Since the subretinal PVA stimulates retinal  
94 neurons that are within close proximity to the electrode (Fransen et al., 2014), we focused our  
95 analysis on inner retinal cells that are likely activated by the PVA device. Rod bipolar cells and  
96 cholinergic amacrine cells represent well defined populations of cells with robust cellular

97 markers to assess overall inner retinal health. We also assessed glial reaction in tissues within  
98 and distal to the implant site from 16 to 26 weeks post implantation in the S334ter-3 and 4  
99 weeks post implantation in the RCS rat. Our results suggest that both the mPVA and bPVA  
100 designs are well tolerated and preserve the necessary inner retinal circuitry that underlie the  
101 transmission of signals to the RGCs and beyond (Fransen et al., 2014).

## 102 **2. Methods**

### 103 **2.1 Animals and Experimental Groups**

104 All animal procedures were approved by the Institutional Animal Care and Use  
105 Committee and conformed to the ARVO Statement for the Use of Animals in Ophthalmology  
106 and Vision Research. Two models of RP were used: the Royal College of Surgeons (RCS) and  
107 S334ter-3 rats from an in-house breeding colony originated from breeders donated by Dr.  
108 Matthew LaVail (University of California, San Francisco) (LaVail et al., 1975; Mullen and LaVail,  
109 1976).

110 The RCS rats (n=4) were implanted binocularly at 4 weeks of age and terminated 4  
111 weeks post-implantation. RCS rats exhibit a moderate rate of photoreceptor degeneration;  
112 approximately 50% of the initial ONL thickness was present at the age of implantation (LaVail  
113 and Battelle, 1975). Four eyes were implanted with an mPVA device and 4 with a bPVA device.  
114 The eyes were divided such that all bPVA-implanted eyes were processed as frozen sections  
115 for retinal cross-sections and half the mPVA eyes processed similarly with the remaining  
116 prepared as retinal flat mounts.

117 S334ter-3 rats were implanted monocularly (right eye) with either an mPVA (n=4) or a  
118 bPVA (n=7) from 6 to 12 weeks of age and were terminated at 22 to 32 weeks of age (16-26  
119 weeks of implantation). Monocular implantation accommodated superior colliculus recordings  
120 that are reported elsewhere (Fransen et al., 2014). The S334ter-3 is a rapid degeneration model



121 and most photoreceptors had degenerated at the time of implantation (McGill et al., 2012). All  
122 S334ter-3 eyes were processed as frozen sections. Additional cross sections were analyzed  
123 from three age-matched unimplanted control eyes from each RP strain, as well as 3 eyes from  
124 8-week-old Long Evans wild-type rats acquired from Charles River.

## 125 **2.2 Overview of Devices**

126 Two types of PVA were explored: mPVA and bPVA (Mathieson et al., 2012; Pardue et  
127 al., 2005b). mPVA devices, provided by Optobionics, Inc (Glen Ellyn, IL), were fabricated using  
128 previously described thin-film fabrication methods (Chow et al., 2001). The mPVA is a 1 mm  
129 diameter silicon disk, 25  $\mu\text{m}$  thick, containing 1200 microphotodiodes with active electrodes on  
130 one face and a common return electrode on the back, both coated with iridium oxide (Chow et  
131 al., 2001). The bPVA device's photovoltaic arrays were composed of triple-diode pixels  
132 fabricated on a silicon wafer. Each pixel contains an active electrode in its center and a return  
133 electrode at the circumference. Upon illumination with a pulse of light, each pixel generates a bi-  
134 phasic pulse of electric current flowing through the tissue between electrodes, primarily  
135 stimulating the inner nuclear layer (INL) cells (Fransen et al., 2014). Electrodes were coated in  
136 iridium oxide and the details of manufacturing methods of the bPVA were published previously  
137 (Wang et al., 2012). Five- $\mu\text{m}$  wide gaps were etched between adjacent pixels for electrical  
138 isolation and to improve nutrients flow through the implant (Mathieson, et al. 2012). The bPVA  
139 device measured 0.8 x 1.2 mm and was 30- $\mu\text{m}$  thick. bPVA devices were left in retinal tissue for  
140 histological analysis due to tissue destruction caused by removal.

141

## 142 **2.3 Surgical Procedure**

143 The surgical methods employed for implantation of the PVAs into the subretinal space  
144 have been described previously (Pardue et al., 2005b). Briefly, rats were anesthetized

145 [ketamine (60 mg/kg) and xylazine (7.5 mg/kg)] and placed into a sterile field. A traction suture  
146 was made at the superior limbus and the eye was rotated inferiorly. A ~1.0 mm incision was  
147 made in the superior globe reaching the vitreous. The eye was hydrated with a drop of saline,  
148 and a 10 minute waiting period was observed which allowed the retina to detach from the RPE.  
149 The PVA was then slid into the subretinal space with the electrodes in contact with the retina.  
150 Successful subretinal placement was confirmed via fundus examination and subsequent  
151 spectral domain-ocular coherence tomography (SD-OCT) imaging (Heidelberg HRA+OCT,  
152 Carlsbad, CA) (Fransen et al., 2014). Implants rested in the superior-temporal retina from 0.5 to  
153 1 mm from the optic nerve head.

## 154 **2.4 Immunohistochemistry**

### 155 **2.4.1 Cross-sections**

156 Following anesthesia [ketamine (60 mg/kg)/xylazine (7.5 mg/kg)] and sacrifice [390  
157 mg/mL pentobarbital sodium (Euthasol, Virbac AH, Inc., Fort Worth, TX)], eyes were  
158 immediately enucleated and fixed in 4% paraformaldehyde for 30 minutes. The posterior eyecup  
159 was bisected in the superior/inferior plane near the optic nerve, ensuring that the entire implant  
160 was intact and present in only one of the two resulting halves (Figure 1A). mPVA devices were  
161 gently extracted from the subretinal space using hydrodissection. bPVAs, which contain gaps  
162 through which the retinal tissue migrates (Palanker et al., 2004), were left in place to preserve  
163 retinal morphology around the implant. The tissue was cryoprotected overnight in 30% sucrose  
164 in 0.1M PBS and frozen in embedding medium (O.C.T. Tissue-Tek®, Sakura Finetek, Tokyo).  
165 Retinal sections in the superior/inferior plane (20-30  $\mu$ m) were cut on a cryostat and thaw-  
166 mounted on glass slides. Sections containing the implant site were mounted on the same slide  
167 with sections from the corresponding non-implanted half (referred to as “distal” tissue) so that  
168 both sections received equal reagent exposure.

169 Table 1 lists the antibodies used, along with working dilutions and sources. Rod bipolar  
170 cells were labeled with anti-protein kinase C alpha subunit (PKC $\alpha$ ) (Kosaka et al., 1998). Müller  
171 glial reaction in response to ocular stress was assessed with antibodies to glial fibrillary acidic  
172 protein (GFAP) (Bringmann et al., 2006). Finally, cholinergic amacrine cells and IPL lamination  
173 patterns were visualized with anti-choline acetyltransferase (ChAT) antibodies (Dijk and  
174 Kamphuis, 2004). The incubation protocol has been described previously (Lee et al., 2008).  
175 Briefly, following a wash in 1.0 M PBS slides were blocked for 1 hour at room temperature (10%  
176 donkey serum, 1% BSA, and 1% Triton X-100 in 1.0 M PBS). Primary and secondary antibodies  
177 were diluted in 1.0 M PBS containing 0.5% Triton X-100. Sections were incubated with primary  
178 antibodies overnight at 4°C and secondary antibodies for 2 hours at room temperature.  
179 Fluorescent secondary antibodies included donkey-anti-rabbit-DyLight® 488 (Abcam,  
180 Cambridge, MA) and donkey-anti-goat-DyLight® 594 (Abcam, Cambridge, MA), both diluted  
181 1:300. Sections were stained with DAPI, mounted with mounting medium (VectaShield® Hard  
182 Set, Vector Laboratories, Inc., Burlingame, CA), and coverslipped.

183 Sections were visualized and images taken on a confocal microscope (Eclipse Ti  
184 microscope with D-Eclipse C1 confocal controller, Nikon, Tokyo). Z-stack images spanning the  
185 section thickness at 1  $\mu$ m intervals were captured using a 40 X oil immersion lens directly under  
186 the implant site (“implanted”), immediately adjacent to the implant site (“adjacent”), and “distal”  
187 tissue from the non-implanted portion of the eye (see Figure 1A). Images of unimplanted control  
188 tissue were acquired from central, superior retinal sections. The Z-stack images were  
189 condensed into max-intensity volume projections and processed using commercial software  
190 (ImageJ, NIH, Bethesda, MD and Photoshop™6.0, Adobe Systems, Inc., San Jose, CA). For  
191 comparisons of cross sections, extended-focus confocal images were composed of a stack of  
192 26 images along the z-axis. ChAT flat mounted extended-focus confocal images were  
193 comprised of a stack of 5 planes, each 1  $\mu$ m thick. Pinhole size, gain, photo multiplier, and

194 offset of the confocal microscope were standardized within experimental groups. Brightness and  
195 contrast optimization was applied equally across all images, except images of GFAP-labeled  
196 sections in which no optimization was performed.

#### 197 **2.4.2 Quantification**

198 Digital confocal cross-sections were analyzed using an image program (Image J,  
199 National Institute of Health, Bethesda, MA). Cross-sections of immuno-labeled S334ter-3  
200 retinas, implanted with either mPVA or bPVA were quantified in the following ways: 1) the length  
201 of PKC $\alpha$  labeled rod bipolar cells were measured from the center of the soma to the axon  
202 terminals, 2) intensity of GFAP immunofluorescence was measured, and 3) the number of INL-  
203 placed and displaced (in RGC layer) ChAT-positive amacrine nuclei were counted. For each  
204 quantification, at least 2 sections from 2-4 retinas were analyzed. Triplicate measurements of  
205 rod bipolar cells from summed z-stack PKC $\alpha$ -labeled images were made on each section and  
206 averaged. GFAP immunoreactivity was quantified by measuring the intensity of a 55 x 40  $\mu$ m  
207 region of interest (ROI) beginning at the retinal ganglion cell layer extending into the inner  
208 plexiform layer and normalized to a background region without tissue of similar size. PKC $\alpha$  and  
209 GFAP data was normalized to the distal regions to compare implant designs between different  
210 ages. ChAT-labeled z-stacks were summed and the number of ChAT positive nuclei was  
211 measured along a 150- $\mu$ m length on each section.

212 Statistical comparisons between mPVA and bPVA devices from each retinal region were  
213 made with two-way repeated measures ANOVA using Holm-Sidak post-hoc comparisons  
214 (Sigmastat v3.5 ,Systat Software, San Jose, CA).

#### 215 **2.4.3 Flat mounts**

216 A subset of RCS eyes was processed as flat mounts, as described previously (Bernstein  
217 and Guo, 2011), with the following modifications. Eyes were enucleated and fixed in 4%

218 paraformaldehyde for 2 hours. The posterior eye cups were digested in hyaluronidase (1mg/mL;  
219 Sigma-Aldrich, St. Louis, MO) diluted 1:500 in 1.0 M PBS for 30 minutes. The retinas were  
220 carefully dissected from the retinal pigment epithelium (RPE), washed twice in PBST (0.5%  
221 Triton X-100 in 1.0M PBS), and then frozen in PBST at -80°C for 15 minutes. After thawing  
222 slowly at room temperature, the retina was washed twice in PBST, blocked (10% donkey serum,  
223 0.25% Triton X-100 in 1.0M PBS) for 4 hours at room temperature, and incubated in anti-ChAT  
224 antibody (Table 1) overnight at 4°C. After 3 washes in PBST, donkey-anti-goat-DyLight® 594  
225 secondary antibody (1:300; Abcam, Cambridge, MA) was applied for 1 hour at room  
226 temperature. Following additional washes, retinas were stained with DAPI, cut into a cloverleaf  
227 shape, and flattened on glass slides with the RGC layer face up. The retinas were mounted with  
228 mounting medium (VectaShield® Hard Set, Vector Laboratories, Inc., Burlingame, CA) and  
229 coverslipped.

230 The flat mounts were imaged using the confocal system, as described above, to  
231 generate Z-stack images over the implant site and distal regions of the same retina. 3D  
232 recreations were assembled and rotated using the 3D Viewer Plugin (ImageJ, NIH, Bethesda,  
233 MD). Contrast and brightness were optimized equally across images (Photoshop™6.0, Adobe  
234 Systems, Inc., San Jose, CA).

### 235 **3. Results**

#### 236 **3.1 Rod bipolar cells maintained in both implant designs and RP models**

237 Rod bipolar cells were labeled for PKC $\alpha$  in both RCS and S334ter-3 rat eyes implanted  
238 with either PVA design. Figure 1A shows a fundus image of an mPVA in an RCS rat and the  
239 superimposed colored lines indicate the areas of the retina sampled in each of the subsequent  
240 figures. Blue indicates the area within the implant site, red the area adjacent to and green the  
241 area distal to the implant site.

242 Figure 1 shows representative images of PKC $\alpha$  positive rod bipolar cells in wild-type  
243 (WT) (Figure 1B) and RCS rat retinas. An unimplanted RCS retina is shown in Figure 1F. The  
244 unimplanted and the implanted RCS retinas exhibited atrophy of rod bipolar cell dendritic tufts  
245 relative to WT. In implanted retinas, this was the case both within and outside implant sites. In  
246 all RCS retinas, rod bipolar cells retained the other aspects of their characteristic morphology;  
247 their somas were located near the outer margin of the INL and axon terminals in the distal IPL.  
248 In addition, they persisted across the retina, including within the implant site regardless of  
249 device design (Figure 1C, G). There were no apparent disruptions of rod bipolar cell morphology  
250 between implant site, adjacent, and distal sites for both bPVA and mPVA implants (compare  
251 Figure 1 C,G to D,H to E,I).

252 Implantation of subretinal devices in S334ter-3 rats had no effect on rod bipolar cell  
253 morphology. Unimplanted S334ter-3 control retinas (Figure 2E) showed a complete loss of rod  
254 bipolar cell dendritic arbors, disorganization of their somas, and a considerably thinner INL  
255 compared to WT (Figure 2A); demonstrating a more advanced retinal degeneration compared to  
256 RCS rats (Figures 1F and 2E). Similarly, S334ter-3 morphology of rod bipolar cells was  
257 comparable regardless of PVA design (Figure 2B-D and 2F-H). S334ter-3 rod bipolar cells  
258 retained their characteristic morphology with somas near the outer margin of the INL and axon  
259 terminals in the distal IPL. In addition, there was no apparent disruption of rod bipolar cell  
260 morphology between implant site, adjacent, and distal sites in the S334ter-3 rat (Figures 2B-D  
261 and F-H), regardless of device design. Quantification of the length of PKC $\alpha$  labeled rod bipolar  
262 cells in S344ter-3 rats showed no significant differences between mPVA and bPVA implanted  
263 rats or retinal location (Figure 3A; Two-way repeated ANOVA,  $p>0.05$ ).

### 264 **3.2 Cholinergic amacrine cells intact with implantation of PVA devices**

265           RCS and S334ter-3 sections were labeled with ChAT to explore the organization of the  
266 cholinergic amacrine cells and the laminar bands that their processes form in the IPL (Figure 4).  
267 The pattern of ChAT expression indicated that cholinergic amacrine cells survive within the  
268 implant site and both their somas and processes maintain WT IPL lamination patterns, with cell  
269 bodies in both the ganglion cell layer (GCL) and the innermost layer of the INL, and stratified  
270 processes within sublaminae a and b (Figure 4). RCS and S334ter-3 tissue showed identical  
271 expression patterns in unimplanted control, implanted, adjacent, and distal retinal tissue with  
272 implantation of the bPVA (Figure 4B-I). mPVA-implanted retinas maintained this typical pattern  
273 (data not shown). Counts of ChAT labeled nuclei in S334ter-3 eyes in both the INL and ganglion  
274 cell layer had a trend towards being lower in mPVA than bPVA, but did not differ statistically  
275 (Figure 3C, 3D; Two-way repeated ANOVA,  $p=0.111$  and  $p = 0.112$ , respectively). ChAT  
276 expression pattern also was examined *en face* in retinal flat mounts in a subset of RCS rats  
277 (Figure 5). The general distribution of ChAT-labeled cells was consistent between control and  
278 both mPVA implanted retinas for ChAT-labeled cells in both the INL and ganglion cell, which  
279 tiled the retina in a mosaic fashion as expected (Figure 5A vs 5B and 5C vs 5D, respectively).

### 280 **3.3 Müller cell glial reaction within normal limits after implantation**

281           Glial reaction within RCS and S334ter-3 retina was evaluated using expression of GFAP  
282 (Figure 6). RCS age-matched unimplanted retinas (Figure 6A) displayed strong GFAP labeling  
283 in Müller glial processes that extended from the nerve fiber layer (NFL) to the partially  
284 degenerated ONL. In bPVA implanted RCS retinas at 4 weeks post implantation (Figure 6B-D),  
285 the glial reaction within the implant site was similar to the reaction in adjacent and distal regions;  
286 we observed little to no additional glial scarring around the implant (Figure 6B). In fact, in many  
287 cases, GFAP labeling appeared to be less pronounced at the implant site (Figure 6B) relative to  
288 distal areas (Figure 6D). Similar results were found with mPVA devices (data not shown).

289 S334ter-3 age-matched unimplanted retinas showed intense GFAP labeling at the outer  
290 edge of the INL that was not seen in RCS retina (Figure 6A, E, I). This is consistent with the  
291 faster degeneration in this model and the formation of a glial seal that occurs after total  
292 photoreceptor degeneration (Jones et al., 2003). While glial reaction was widespread,  
293 persistent, and uniform in all S334ter-3 tissue, there was no noticeable difference in expression  
294 of GFAP by Müller glia in bPVA implanted retinas adjacent or distal to the implants (Figure 6J-  
295 L). Although the spatial extent of GFAP reaction was similar in mPVA implanted retinas (Figure  
296 6F-H), we observed a significant increase in GFAP intensity in mPVA devices compared to  
297 bPVA (Figure 3B; Two-way repeated ANOVA, main effect of device,  $F(1, 15) = 14.38, p=0.02$ ;  
298 Figure 3B). The differences were greatest over the implant regions with bPVA-implanted retinas  
299 having less GFAP immunoreactivity.

#### 300 **4. Discussion**

301 The use of subretinal prostheses for the restoration of vision in patients with RP or AMD  
302 depends upon an intact inner retina (O'Brien et al., 2012). Thus, it is critical that implantation of  
303 a subretinal device does not cause a loss of inner retinal cells or excessive gliosis/fibrosis, as  
304 both would interfere with the retinal-prosthesis interface. We have shown that a functional  
305 connection that requires synaptic transmission within the inner retina drives PVA evoked  
306 responses in the superior colliculus (Fransen et al., 2014). Here we show that the morphological  
307 basis for this connectivity is an intact inner retina in subretinally-implanted m- and bPVA  
308 devices. In addition, we show that morphology is maintained in two RP rat models, one with  
309 direct photoreceptor degeneration, the other with RPE dysfunction induced photoreceptor  
310 degeneration. This indicates that the effect we observe is general. We assessed rod bipolar  
311 cells because they represent the primary transmission pathway from the PVA to the RGCs and  
312 cholinergic amacrine cells because they are one of the most numerous amacrine cells and their  
313 processes form well known sublaminae in the the IPL. Together the two measures provide a



314 general assessment of inner retinal cell organization. While it is well-established that the  
315 degenerating retina undergoes remodeling when all photoreceptors are lost (Gargini et al.,  
316 2007; Marc et al., 2003; Strettoi et al., 2002), we show that in these models, rod bipolar cells  
317 and cholinergic amacrine cells within the implant site continue to exhibit typical and well-  
318 preserved morphology. Both their somata and processes within the IPL show normal  
319 localization and lamination. Previous studies show that normal retinas respond to both acute  
320 epiretinal electrical stimulation (Ray et al., 2009; Ray et al., 2011), or chronic subretinal  
321 implantation (Chow et al., 2001; Pardue et al., 2001; Tamaki et al., 2008; Yu et al., 2009) with  
322 an upregulation of GFAP expression and degenerative changes to the dendrites of rod bipolar  
323 cells. One study in which photosensitive dye-coupled film was subretinally implanted into RCS  
324 rat eyes showed preservation within the implant site of rod bipolar cell morphology via PKC $\alpha$   
325 labeling (Alamusi et al., 2013), consistent with the findings we report here.

326         The increase in GFAP labeling in all unimplanted RCS and S334ter-3 retinas compared  
327 to WT (images not shown) is consistent with previous reports on retinal remodeling during  
328 degeneration (Marc and Jones, 2003; Zhao et al., 2012). Importantly, GFAP labeling in and  
329 around the implant site was similar to distal areas, suggesting that the glial reaction was not  
330 augmented by the presence of the PVA. Previous immunohistochemical studies of subretinal  
331 implants in animals with normal retinas have shown an increase in GFAP expression within the  
332 implant site (Chow et al., 2001; Pardue et al., 2001; Tamaki et al., 2008; Yu et al., 2009). It is  
333 feasible that any upregulation in GFAP due to implantation is masked when extensive gliosis  
334 due to photoreceptor degeneration is already present. Quantification of GFAP  
335 immunofluorescence showed a significant decrease in S334ter-3 retinas implanted with bPVAs  
336 compared to mPVAs. This may indicate that the gap design of the bPVA is more biocompatible  
337 with the retina and reduces the stress response. As the PVA devices are active and present  
338 electrical current to the underlying inner retina in response to light, it is possible that GFAP

339 expression in the Müller glia is tempered by neuroprotective effects of subretinal electrical  
340 stimulation, which have been characterized previously (Ciavatta et al., 2013; Pardue et al.,  
341 2005a; Pardue et al., 2005b).

342           The persistence of inner retinal cells and their intact organization under the implanted  
343 device are consistent with our finding that PVA evoked responses are retained in the superior  
344 colliculus and require inner retinal synaptic transmission (Fransen et al., 2014). Structural  
345 integrity is critical to the success of function using this subretinal approach to visual restoration.  
346 The presence of normal IPL sublamination suggests that other circuits that modulate the  
347 excitatory signal are retained and may provide even better RGC and central signals. When  
348 translated to the clinic, implantation will be performed at mid to late stage of photoreceptor  
349 degeneration, similar to the implantation stages used here in the RCS and S334ter-3 rats,  
350 respectively. The morphology of the retina implanted with both PVAs was similar, which also is  
351 consistent with the functional results (Fransen et al., 2014) suggesting good compatibility at  
352 both stages of degeneration.

353           The development of the next-generation bPVA is intended to improve upon the design of  
354 the mPVA device, which has already been implanted in human patients (Chow et al., 2010;  
355 Chow et al., 2004). Bipolar design of the pixel electrodes provides much tighter confinement of  
356 electric field, and appears to improve spatial resolution, compared to monopolar arrangement in  
357 mPVAs (Fransen et al., 2014). Our comparisons between mPVA- and bPVA-implanted retinas  
358 and the reduced glial reaction in the retinas implanted with the bPVA device with the gaps  
359 between pixels suggests improved biocompatibility and may indicate a longer duration of the  
360 interface between the device and the retina, which needs to be tested empirically.

## 361 **5. Conclusions**

362 We found that both mPVA and bPVA devices implanted into the subretinal space were  
 363 well tolerated by the inner retina in two rat models of RP with regard to rod bipolar, cholinergic  
 364 amacrine, and Müller cell morphology. This initial analysis could be complemented with assays  
 365 of other cell types (such as cone bipolar cells, horizontal cells as well as other amacrine cell  
 366 classes). Other functional analyses could be aimed at examining the RGC responses and the  
 367 timing and spatial distribution of their excitatory and inhibitory inputs. With our findings this  
 368 would provide a complete understanding of the morphological and functional status of the inner  
 369 retina in contact with the prosthesis.

370 **Acknowledgements**

371 Funding was provided by the National Institutes of Health (R01-EY-018608), the Air Force  
 372 Office of Scientific Research (FA9550-04), NIH CTSA (UL1 RR025744, Stanford Spectrum  
 373 fund) and a Stanford Bio-X IIP grant. K.M. was supported by an SU2P fellowship as part of an  
 374 RCUK Science Bridges award. J.F. was supported by an NIH T32 grant (5 T32 HL 76138-09).  
 375 M.P. was supported by a Research Career Scientist Award from the Department of Veterans  
 376 Affairs.

377

378 **Table 1: Primary antibodies used in this study to characterize inner retinal health.**

Antigen	Antiserum	Source	Working Dilution	Cellular Target
PKC $\alpha$	Polyclonal rabbit anti-PKC $\alpha$	Santa Cruz Biotechnology, Inc., Dallas, TX	1:2000	Rod bipolar cells
GFAP	Polyclonal rabbit anti-GFAP	Abcam, Cambridge, MA	1:500	Glial reaction in retinal Müller cells
ChAT	Polyclonal goat anti-ChAT	Millipore, Billerica, MA	1:100	Cholinergic amacrine cells

379

380 **Figures Captions**

381 **Figure 1.** A) Sample fundus image of an RCS rat eye implanted subretinally with an mPVA.  
382 White dotted line indicates location of the cut made in the superior to inferior plane bisecting the  
383 posterior eye cup into implanted and non-implanted halves. “Implanted” region is indicated by  
384 the blue line. The area immediately “adjacent” to the implant site is shown by the red line. The  
385 green line displays an area opposite the implant within the non-implanted half, referred to as a  
386 “distal” area. The implant is 1mm in diameter. PKC $\alpha$  labeling in retinal cross-sections from WT  
387 rats (B), unimplanted control RCS rats at 2 months of age (F), RCS rats implanted from 4 to 8  
388 weeks postnatal with a bPVA (C-E) and or mPVA (G-I). Rod bipolar cells are present with well-  
389 preserved morphology and localization at the implant site (C and G) relative to adjacent (D and  
390 H) and distal (E and I) regions. Implanted eyes show PKC $\alpha$  labeling consistent with that of age-  
391 matched unimplanted RCS controls (F). Wild-type retinas (B) appear to exhibit more intact  
392 dendritic tufts, but somata and axon terminal localization is comparable to that in RCS tissue.  
393 Insets 1B, 1C, 1 F & 1G show magnified images of the dendritic tufts in the OPL. ONL=outer  
394 nuclear layer, OPL=outer plexiform layer, INL=inner nuclear layer, IPL=inner plexiform layer,  
395 GCL=ganglion cell layer. Scale bar=50 $\mu$ m.

396 **Figure 2.** PKC $\alpha$  labeling in retinal cross-sections from S334ter-3 rats implanted with a bPVA (B-  
397 D, implanted from 7 to 27 weeks postnatal) or mPVA (F-H, implanted from 6 to 27 weeks  
398 postnatal). Implanted sections (B and F) show rod bipolar cell morphology that is comparable to  
399 that in adjacent (C and G) and distal (D and H) areas. The morphology and localization of these  
400 sections is consistent with that seen in age-matched unimplanted S334ter-3 controls (E).  
401 However, all S334ter-3 tissues exhibit virtually complete loss of the ONL and rod bipolar cell  
402 dendrites, both of which are still evident in wild-type retina (A). Scale bar=50 $\mu$ m.

403 **Figure 3.** PKC $\alpha$ , GFAP, and ChAT labeling quantification. The relative length of PKC $\alpha$ -labeled  
404 bipolar cells (A) did not show significant differences between retinal region or implant types. The

405 intensity of GFAP immunoreactivity (B) did not show significant differences between the retinal  
406 location within each implant type, but did show a difference between implant types (Two-way  
407 repeated ANOVA,  $F(1, 15) = 14.38$   $p = 0.02$ ,  $n = 6$ ). Immunoreactivity was normalized to the  
408 distal position for the PKC $\alpha$  and GFAP labeling. ChAT immunoreactive cell counts did not show  
409 significant differences between retinal location or implant type for either INL placed (C) or  
410 displaced (D) cholinergic amacrine cells. Error bars represent standard error of the mean.

411 **Figure 4.** ChAT labeling in retinal cross-sections from RCS eyes (C-E, implanted from 4 to 8  
412 weeks postnatal) and S334ter-3 eyes (G-I, implanted from 7 to 27 weeks postnatal) with bPVA  
413 devices. Both RCS (B-E) and S334ter-3 sections (F-I), like wild-type (A), show typical  
414 cholinergic amacrine cell morphology with somata in the INL and GCL and processes in a dual-  
415 lamination pattern within the IPL. ChAT labeling patterns in implanted areas (C and G) are  
416 identical to those in adjacent (D and H), distal (E and I), Scale bar=50 $\mu$ m.

417 **Figure 5.** ChAT-labeled retinal flat mounts from RCS rats implanted from 4 to 8 weeks postnatal  
418 with an mPVA device (C and D) compared to unimplanted control eyes (A and B). *En face* view  
419 of control INL placed (A) and implanted INL placed (C) ChAT positive amacrine cells shows  
420 similar cholinergic amacrine cell distribution with consistent density. Similarly, labelling patterns  
421 of ChAT positive amacrine cells in the ganglion cell layer were consistent between control (B)  
422 and implanted (D) retinas. Scale bar=50 $\mu$ m.

423

424 **Figure 6.** GFAP labeling in retinal cross-sections from RCS (B-D) with bPVA and S334ter-3  
425 eyes with mPVA (F-H) and bPVA (K-L) devices. RCS were implanted 4 to 8 weeks postnatally,  
426 while the S334ter-3 animals were implanted at 12 to 32 weeks. Glial reaction is widespread in  
427 all RCS tissue (A-D), but implanted areas (B) do not show increased GFAP labeling in  
428 comparison with adjacent (C), distal (D), and age-matched unimplanted control (A) sections.  
429 Similar to RCS tissue, S334ter-3 sections (E-L) show widespread gliosis due to photoreceptor

430 degeneration. However, GFAP labeling is not augmented in implanted regions (F and J) relative  
431 to adjacent (G and K), distal (H and L), and age-matched unimplanted control section (E).  
432 S334ter-3 retinas display a characteristic glial seal above the INL, not seen in wild-type retinas  
433 (data not shown), consistent with advanced photoreceptor degeneration. NFL=nerve fiber layer.  
434 Scale bar=50 $\mu$ m.

435

436

437

438

439

440

441

442

443

444

445

446

447

448

449

450

451

452

453

454

455

456 **References**

- 457 Adkins, A., Wang, W., Kaplan, H., Emery, D., Fernandez de Castro, J., Lee, S.-J., Huie, P.,  
458 Palanker, D., McCall, M., Pardue, M., 2013. Morphological comparisons of flat and 3-  
459 dimensional subretinal photovoltaic arrays in rat and pig models of retinitis pigmentosa.  
460 Invest. Ophthalmol. Vis. Sci. 54, 1038.
- 461 Alamusi, Matsuo, T., Hosoya, O., Tsutsui, K.M., Uchida, T., 2013. Behavior tests and  
462 immunohistochemical retinal response analyses in RCS rats with subretinal implantation  
463 of Okayama-University-type retinal prosthesis. J. Artif. Organs 16, 343-351.
- 464 Asher, A., Segal, W.A., Baccus, S.A., Yaroslavsky, L.P., Palanker, D.V., 2007. Image  
465 processing for a high-resolution optoelectronic retinal prosthesis. IEEE Trans. Biomed.  
466 Eng. 54, 993-1004.
- 467 Bernstein, S.L., Guo, Y., 2011. Changes in cholinergic amacrine cells after rodent anterior  
468 ischemic optic neuropathy (rAION). Invest. Ophthalmol. Vis. Sci. 52, 904-910.
- 469 Bi, A.D., Cui, J.J., Ma, Y.P., Olshevskaya, E., Pu, M.L., Dizhoor, A.M., Pan, Z.H., 2006. Ectopic  
470 expression of a microbial-type rhodopsin restores visual responses in mice with  
471 photoreceptor degeneration. Neuron 50, 23-33.
- 472 Bringmann, A., Pannicke, T., Grosche, J., Francke, M., Wiedemann, P., Skatchkov, S.N.,  
473 Osborne, N.N., Reichenbach, A., 2006. Muller cells in the healthy and diseased retina.  
474 Prog. Retin. Eye Res. 25, 397-424.
- 475 Busskamp, V., Picaud, S., Sahel, J.A., Roska, B., 2012. Optogenetic therapy for retinitis  
476 pigmentosa. Gene Ther. 19, 169-175.
- 477 Chow, A.Y., Bittner, A.K., Pardue, M.T., 2010. The artificial silicon retina in retinitis pigmentosa  
478 patients (an American Ophthalmological Association thesis). Trans. of the Am.  
479 Ophthalmol. Soc. 108, 120-154.

480 Chow, A.Y., Chow, V.Y., Packo, K.H., Pollack, J.S., Peyman, G.A., Schuchard, R., 2004. The  
481 artificial silicon retina microchip for the treatment of vision loss from retinitis pigmentosa.  
482 Arch. Ophthalmol. 122, 460-469.

483 Chow, A.Y., Pardue, M.T., Chow, V.Y., Peyman, G.A., Liang, C., Perlman, J.I., Peachey, N.S.,  
484 2001. Implantation of silicon chip microphotodiode arrays into the cat subretinal space.  
485 IEEE Trans. Neural Syst. Rehabil. Eng. 9, 86-95.

486 Ciavatta, V.T., Mocko, J.A., Kim, M.K., Pardue, M.T., 2013. Subretinal electrical stimulation  
487 preserves inner retinal function in RCS rat retina. Mol. Vis. 19, 995-1005.

488 Cicione, R., Shivdasani, M.N., Fallon, J.B., Luu, C.D., Allen, P.J., Rathbone, G.D., Shepherd,  
489 R.K., Williams, C.E., 2012. Visual cortex responses to suprachoroidal electrical  
490 stimulation of the retina: effects of electrode return configuration. J. Neural Eng. 9,  
491 036009.

492 Dijk, F., Kamphuis, W., 2004. An immunocytochemical study on specific amacrine cell  
493 subpopulations in the rat retina after ischemia. Brain Res. 1026, 205-217.

494 Fransen, J. W., Pangen, G., Pardue, M.T., McCall, M.A. 2014. Local signaling from a retinal  
495 prosthetic in a rodent retinitis pigmentosa model in vivo. J. Neural Eng. 11, 046012.

496 Garg, S.J., Federman, J., 2013. Optogenetics, visual prosthesis and electrostimulation for  
497 retinal dystrophies. Curr. Opin. Ophthalmol. 24, 407-414.

498 Gargini, C., Terzibasi, E., Mazzoni, F., Strettoi, E., 2007. Retinal organization in the retinal  
499 degeneration 10 (rd10) mutant mouse: a morphological and ERG study. J. Comp.  
500 Neurol. 500, 222-238.

501 Grünert, U., Martin, P.R., 1991. Rod bipolar cells in the macaque monkey retina:  
502 immunoreactivity and connectivity. J Neurosci. 11, 2742-2758.

503 Hartong, D.T., Berson, E.L., Dryja, T.P., 2006. Retinitis pigmentosa. Lancet 368, 1795-1809.

504 Humayun, M.S., Dorn, J.D., da Cruz, L., Dagnelie, G., Sahel, J.A., Stanga, P.E., Cideciyan,  
505 A.V., Duncan, J.L., Elliott, D., Filley, E., Ho, A.C., Santos, A., Safran, A.B., Arditi, A., Del



506 Priore, L.V., Greenberg, R.J., Argus, I.I.S.G., 2012. Interim results from the international  
507 trial of Second Sight's visual prosthesis. *Ophthalmology* 119, 779-788.

508 Humayun, M.S., Prince, M., de Juan, E., Barron, Y., Moskowitz, M., Klock, I.B., Milam, A.H.,  
509 1999. Morphometric analysis of the extramacular retina from postmortem eyes with  
510 retinitis pigmentosa. *Invest. Ophthalmol. Vis. Sci.* 40, 143-148.

511 Isago, H., Sugano, E., Wang, Z., Murayama, N., Koyanagi, E., Tamai, M., Tomita, H., 2012.  
512 Age-Dependent Differences in Recovered Visual Responses in Royal College of  
513 Surgeons Rats Transduced with the Channelrhodopsin-2 Gene. *J. of Mol. Neurosci.* 46,  
514 393-400.

515 Jensen, R.J., Ziv, O.R., Rizzo, J.F., 2005. Responses of rabbit retinal ganglion cells to electrical  
516 stimulation with an epiretinal electrode. *J. Neural Eng.* 2, S16-21.

517 Jones, B.W., Watt, C.B., Frederick, J.M., Baehr, W., Chen, C.K., Levine, E.M., Milam, A.H.,  
518 Lavail, M.M., Marc, R.E., 2003. Retinal remodeling triggered by photoreceptor  
519 degenerations. *J. Comp. Neurol.* 464, 1-16.

520 Jones, B.W., Marc, R.E., 2005. Retinal remodeling during retinal degeneration. *Exp. Eye Res.*  
521 81, 123-137.

522 Kanda, H., Morimoto, T., Fujikado, T., Tano, Y., Fukuda, Y., Sawai, H., 2004.  
523 Electrophysiological studies of the feasibility of suprachoroidal-transretinal stimulation for  
524 artificial vision in normal and RCS rats. *Invest. Ophthalmol. Vis. Sci.* 45, 560-566.

525 Kosaka, J., Suzuki, A., Morii, E., Nomura, S., 1998. Differential localization and expression of  
526 alpha and beta isoenzymes of protein kinase C in the rat retina. *J. Neurosci. Res.* 54,  
527 655-663.

528 LaVail, M.M., Battelle, B.A., 1975. Influence of eye pigmentation and light deprivation on  
529 inherited retinal dystrophy in the rat. *Exp. Eye Res.* 21, 167-192.

530 LaVail, M.M., Sidman, R.L., Gerhardt, C.O., 1975. Congenic strains of RCS rats with inherited  
531 retinal dystrophy. *J. Hered.* 66, 242-244.

532 Lee, E.J., Padilla, M., Merwine, D.K., Grzywacz, N.M., 2008. Developmental regulation of the  
533 morphology of mouse retinal horizontal cells by visual experience. *Eur. J. Neurosci.* 27,  
534 1423-1431.

535 Lin, B., Koizumi, A., Tanaka, N., Panda, S., Masland, R.H., 2008. Restoration of visual function  
536 in retinal degeneration mice by ectopic expression of melanopsin. *Proc. Natl. Acad. Sci.*  
537 U.S.A. 105, 16009-16014.

538 Mandel, Y., Goetz, G., Lavinsky, D., Huie, P., Mathieson, K., Wang, L., Kamins, T., Galambos,  
539 L., Manivanh, R., Harris, J., Palanker, D., 2013. Cortical responses elicited by  
540 photovoltaic subretinal prostheses exhibit similarities to visually evoked potentials. *Nat.*  
541 *Commun.* 4, 1980.

542 Marc, R.E., Jones, B.W., 2003. Retinal remodeling in inherited photoreceptor degenerations.  
543 *Mol. Neurobiol.* 28, 139-147.

544 Marc, R.E., Jones, B.W., Anderson, J.R., Kinard, K., Marshak, D.W., Wilson, J.H., Wensel, T.,  
545 Lucas, R.J., 2007. Neural reprogramming in retinal degeneration. *Invest. Ophthalmol.*  
546 *Vis. Sci.* 48, 3364-3371.

547 Marc, R.E., Jones, B.W., Watt, C.B., Strettoi, E., 2003. Neural remodeling in retinal  
548 degeneration. *Prog. Retin. Eye Res.* 22, 607-655.

549 Mathieson, K., Loudin, J., Goetz, G., Huie, P., Wang, L., Kamins, T.I., Galambos, L., Smith, R.,  
550 Harris, J.S., Sher, A., Palanker, D., 2012. Photovoltaic Retinal Prosthesis with High Pixel  
551 Density. *Nat. Photonics* 6, 391-397.

552 McGill, T.J., Prusky, G.T., Douglas, R.M., Yasumura, D., Matthes, M.T., Lowe, R.J., Duncan,  
553 J.L., Yang, H., Ahern, K., Daniello, K.M., Silver, B., LaVail, M.M., 2012. Discordant  
554 anatomical, electrophysiological, and visual behavioral profiles of retinal degeneration in  
555 rat models of retinal degenerative disease. *Invest. Ophthalmol. Vis. Sci.* 53, 6232-6244.

556 Morimoto, T., Kamei, M., Nishida, K., Sakaguchi, H., Kanda, H., Ikuno, Y., Kishima, H., Maruo,  
557 T., Konoma, K., Ozawa, M., Nishida, K., Fujikado, T., 2011. Chronic Implantation of

558 Newly Developed Suprachoroidal-Transretinal Stimulation Prosthesis in Dogs. Invest.  
559 Ophthalmol. Vis. Sci. 52, 6785-6792.

560 Mullen, R.J., LaVail, M.M., 1976. Inherited retinal dystrophy: primary defect in pigment  
561 epithelium determined with experimental rat chimeras. Science 192, 799-801.

562 O'Brien, E.E., Greferath, U., Vessey, K.A., Jobling, A.I., Fletcher, E.L., 2012. Electronic  
563 restoration of vision in those with photoreceptor degenerations. Clin. Exp. Optom. 95,  
564 473-483.

565 Palanker, D., Huie, P., Vankov, A., Aramant, R., Seiler, M., Fishman, H., Marmor, M.,  
566 Blumenkranz, M., 2004. Migration of retinal cells through a perforated membrane:  
567 implications for a high-resolution prosthesis. Invest. Ophthalmol. Vis. Sci. 45, 3266-3270.

568 Pardue, M.T., Phillips, M.J., Yin, H., Fernandes, A., Cheng, Y., Chow, A.Y., Ball, S.L., 2005a.  
569 Possible sources of neuroprotection following subretinal silicon chip implantation in RCS  
570 rats. J. Neural Eng. 2, S39-47.

571 Pardue, M.T., Phillips, M.J., Yin, H., Sippy, B.D., Webb-Wood, S., Chow, A.Y., Ball, S.L., 2005b.  
572 Neuroprotective effect of subretinal implants in the RCS rat. Invest. Ophthalmol. Vis. Sci.  
573 46, 674-682.

574 Pardue, M.T., Stubbs, E.B., Jr., Perlman, J.I., Narfstrom, K., Chow, A.Y., Peachey, N.S., 2001.  
575 Immunohistochemical studies of the retina following long-term implantation with  
576 subretinal microphotodiode arrays. Exp. Eye Res. 73, 333-343.

577 Ray, A., Colodetti, L., Weiland, J.D., Hinton, D.R., Humayun, M.S., Lee, E.J., 2009.  
578 Immunocytochemical analysis of retinal neurons under electrical stimulation. Brain Res.  
579 1255, 89-97.

580 Ray, A., Lee, E.J., Humayun, M.S., Weiland, J.D., 2011. Continuous electrical stimulation  
581 decreases retinal excitability but does not alter retinal morphology. J. Neural Eng. 8,  
582 045003.

583 Rizzo, J.F., 3rd, 2011. Update on retinal prosthetic research: the Boston Retinal Implant Project.  
584 J. Neuroophthalmol. 31, 160-168.

585 Strettoi, E., Porciatti, V., Falsini, B., Pignatelli, V., Rossi, C., 2002. Morphological and functional  
586 abnormalities in the inner retina of the rd/rd mouse. J. Neurosci. 22, 5492-5504.

587 Strettoi, E., Pignatelli, V., Rossi, C., Porciatti, V., Falsini, B., 2003. Remodeling of second-order  
588 neurons in the retina of rd/rd mutant mice. Vision Research 43, 867–877.

589 Tamaki, T., Matsuo, T., Hosoya, O., Tsutsui, K.M., Uchida, T., Okamoto, K., Uji, A., Ohtsuki, H.,  
590 2008. Glial reaction to photoelectric dye-based retinal prostheses implanted in the  
591 subretinal space of rats. J. Artif. Organs 11, 38-44.

592 Tomita, H., Sugano, E., Yawo, H., Ishizuka, T., Isago, H., Narikawa, S., Kugler, S., Tamai, M.,  
593 2007. Restoration of visual response in aged dystrophic RCS rats using AAV-mediated  
594 channelopsin-2 gene transfer. Invest. Ophthalmol. Vis. Sci. 48, 3821-3826.

595 Uji, A., Matsuo, T., Ishimaru, S., Kajiura, A., Shimamura, K., Ohtsuki, H., Dan-oh, Y., Suga, S.,  
596 2005. Photoelectric dye-coupled polyethylene film as a prototype of retinal prostheses.  
597 Artif. Organs 29, 53-57.

598 Wang, L., Mathieson, K., Kamins, T.I., Loudin, J.D., Galambos, L., Goetz, G., Sher, A., Mandel,  
599 Y., Huie, P., Lavinsky, D., Harris, J.S., Palanker, D.V., 2012. Photovoltaic retinal  
600 prosthesis: implant fabrication and performance. J. Neural Eng. 9, 046014.

601 Wong, Y.T., Chen, S.C., Seo, J.M., Morley, J.W., Lovell, N.H., Suaning, G.J., 2009. Focal  
602 activation of the feline retina via a suprachoroidal electrode array. Vis. Res. 49, 825-833.

603 Yamauchi, Y., Franco, L.M., Jackson, D.J., Naber, J.F., Ziv, R.O., Rizzo, J.F., Kaplan, H.J.,  
604 Enzmann, V., 2005. Comparison of electrically evoked cortical potential thresholds  
605 generated with subretinal or suprachoroidal placement of a microelectrode array in the  
606 rabbit. J. Neural Eng. 2, S48-56.


607 Yu, W., Wang, X., Zhao, C., Yang, Z., Dai, R., Dong, F., 2009. Biocompatibility of subretinal  
608 parylene-based Ti/Pt microelectrode array in rabbit for further artificial vision studies. *J.*  
609 *Ocul. Biol. Dis. Infor.* 2, 33-36.


610 Zhao, T., Li, Y., Weng, C., Yin, Z., 2012. The changes of potassium currents in RCS rat Muller  
611 cell during retinal degeneration. *Brain Res.* 1427, 78-87.

612 Zrenner, E., Stett, A., Weiss, S., Aramant, R.B., Guenther, E., Kohler, K., Miliczek, K.D., Seiler,  
613 M.J., Haemmerle, H., 1999. Can subretinal microphotodiodes successfully replace  
614 degenerated photoreceptors? *Vis. Res.* 39, 2555-2567.


615

616







Figure(s)  
[Click here to download high resolution image](#)









Figure(s)  
[Click here to download high resolution image](#)

